Treatment of autoimmune encephalitis using saterlizumab
Through the combination of Satlizumab and immunosuppressive therapy, the safety risks and insufficient treatment response in anti-NMDAR and anti-LGI1 encephalitis treatment were solved, significantly improved the clinical manifestations and recurrence risks of patients, and provided more effective treatment plan.
Patent Information
- Application Number
- CN202380028068.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-19
- Filing Date
- 2023-01-18
- Publication Date
- 2024-11-05
AI Technical Summary
The existing treatment methods for anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivation 1 (LGI1) encephalitis have safety risks and poor treatment response. There is a lack of effective prospective treatment options for cognitive deficits and insufficient control of epilepsy.
Using Satlizumab as an IL-6 receptor antibody, its efficacy, safety, pharmacokinetics and pharmacodynamics in the treatment of anti-NMDAR and anti-LGI1 encephalitis were evaluated through a phase III randomized double-blind study, combined with Immunosuppressive therapy to reduce the risk of recurrence.
Satlizumab significantly improves the therapeutic effect of patients with anti-NMDAR and anti-LGI1 encephalitis, reduces the risk of recurrence, improves cognitive function and epilepsy control, and provides a safer treatment plan.
Smart Images

Figure CN118900699A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a medicament or pharmaceutical composition for treating autoimmune encephalitis (also referred to as AIE or AE) or reducing the risk of recurrence thereof, comprising an anti-IL-6 receptor antibody or an antigen-binding fragment thereof, wherein the autoimmune encephalitis includes but is not limited to anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivation 1 (LGI1) encephalitis. The present invention also relates to a method for treating the autoimmune encephalitis (AIE) or reducing the risk of recurrence thereof by administering an anti-IL-6 receptor antibody or an antigen-binding fragment thereof to a subject in need thereof, wherein the autoimmune encephalitis includes but is not limited to anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivation 1 (LGI1) encephalitis. Background Art
[0002] Acute encephalitis is a rare and debilitating neurological disorder that occurs in patients of all ages and presents with a rapidly progressive encephalopathy resulting from inflammation of the brain [NPL 1]. Autoimmune encephalitis (AIE) encompasses disorders that are associated with an identifiable etiological driver (usually a neoplasm) as well as those that are considered idiopathic. Paraneoplastic immune-mediated encephalitis syndromes may be associated with antibodies directed against intracellular neuronal proteins (tumor neuronal proteins such as anti-Hu). The pathogenic significance of these disorders is unclear and they often represent syndromes that do not respond well to immunotherapy.
[0003] The identification of antibodies against neuronal cell surface and synaptic proteins that are thought to be directly pathogenic may delineate a population that is generally more responsive to immunotherapy, regardless of the presence of an associated tumor. Of these AIE subtypes, NMDAR- and LGI1-mediated encephalitis are the two most common [NPL 2] and best characterized syndromes.
[0004] NMDAR encephalitis is an immune-mediated disease characterized by a complex neuropsychiatric syndrome, including cognitive impairment and seizures, and the presence of cerebrospinal fluid (CSF) antibodies against the GluN1 subunit of NMDARs. Using mouse models, these antibodies have been shown to crosslink NMDARs, altering their surface dynamics and interactions with other synaptic proteins, and leading to their internalization, with severe impairment of synaptic plasticity and NMDAR network function [NPL 3-6]. The estimated annual incidence of NMDAR encephalitis is 1.5 per million population, with a female predominance (female to male ratio of approximately 8:2) and a median age of onset of 21 years (age range: <1-85 years). Patients present with a range of symptoms that vary depending on the stage of the disease and clinically suggest the diagnosis [NPL 7].
[0005] LGI1 encephalitis is an immune-mediated disease that presents in most patients as limbic encephalitis characterized by subacute memory and behavioral impairments, often accompanied by seizures. It is associated with antibodies against the LGI1 protein. LGI1 encephalitis is more common in middle-aged and elderly men (over 50 years old) [NPL 8]. Most LGI1 protein is expressed in the hippocampus and more broadly in the medial temporal lobe, from where it is secreted into the synaptic space. LGI1 is part of an inhibitory pathway connecting presynaptic voltage-gated K+ channels (VGKCs) and postsynaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) [NPL 9 and NPL 10]. The estimated prevalence of LGI1 encephalitis is 7 per million population [NPL 11], and the estimated incidence is 0.83 per 1 million population [NPL 12].
[0006] There are currently no approved therapies for NMDAR or LGI1 encephalitis. Treatment of NMDAR and LGI1 encephalitis initially involves first-line therapy (e.g., steroids, intravenous immunoglobulin [IVIG], or plasma exchange), as detailed in a recent survey by the Autoimmune Encephalitis Alliance Clinicians Network [NPL 13]. High-dose steroids are most commonly used, but the distribution of first-line therapy for the two most common diseases is very similar, as shown below.
[0007] The principles of escalation, use of second-line therapy, and specific second-line therapy used are similar in both disorders, although steroid responses are more common in LGI1 encephalitis [NPL 14] and long-term steroid use is more commonly used in this disorder.
[0008] Although the majority of patients with cell surface antibody-positive disease achieve stable disease with currently used treatment regimens, no prospective randomized trials have been reported to date for this population, and all treatment approaches are based on anecdotal evidence. Current AIE treatment paradigms have several limitations, highlighting a critical unmet need for treatments with rapid and demonstrated long-term efficacy and safety effects. For example, not all patients respond to these medications, and several drawbacks remain, including cognitive deficits, inadequate seizure relief, dependence on high-dose corticosteroids, and the need for longer-lasting, faster-acting medications. Prospectively generated evidence in AIE is urgently needed to guide treatment selection to address both the acute and long-term effects of this rare neurological disease.
[0009] Humanized antibodies such as tocilizumab are first-generation antibody drugs. By improving first-generation antibody drugs, second-generation antibody drugs with improved efficacy, convenience, and cost-effectiveness are being developed [PTL 2 and PTL 3]. Among the second-generation antibody drugs, Satlizumab (SA237) is a new anti-IL-6 receptor antibody that applies improved technologies such as enhanced antigen binding ability, pharmacokinetics and stability, and reduced immunogenicity risks [PTL 3 and PTL 4].
[0010] Satlizumab is a humanized anti-IL-6 receptor monoclonal antibody with pH-dependent antigen binding. It specifically targets the human IL-6 receptor (IL-6R) and inhibits IL-6 signaling by inhibiting the binding of IL-6 to membrane-bound IL-6R and soluble IL-6R. Satlizumab was constructed by modifying the amino acid sequence of tocilizumab to extend its plasma half-life. Satlizumab also shows a reduced isoelectric point of the antibody molecule and stronger binding to FcRn compared to tocilizumab. In addition, its Fc region has been modified compared to tocilizumab to minimize antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity effector activity.
[0011] The prior art document information related to the invention of this application is as follows.
[0012] Satlizumab has demonstrated efficacy and safety for the treatment of another autoantibody-mediated disease (ie, NMOSD) as monotherapy or as adjunct to immunosuppressive therapy (IST; ie, oral corticosteroids [OCS], azathioprine, or mycophenolate mofetil). A total of 178 participants were included in the double-blind phase of the Phase III study in NMOSD. Of the 178 participants, 104 participants received a 120 mg dose of satlizumab subcutaneously every 4 weeks (Q4W) and 74 participants received placebo. Overall, patients with NMOSD tolerated satlizumab monotherapy or in combination with IST well.
[0013] All currently available treatment options for AIE, including high-dose corticosteroids and cyclophosphamide, present significant potential safety risks. There is no evidence from randomized controlled trials to support treatment decisions. In addition, not all patients respond to currently used medications, and several drawbacks remain, including cognitive deficits, inadequate seizure relief, dependence on high-dose corticosteroids, and the need for longer-lasting, faster-acting medications.
[0014] Citation List
[0015] Patent Literature
[0016] [PTL 1] US2012 / 0039840
[0017] [PTL 2]WO2009 / 041621
[0018] [PTL 3]WO2010 / 035769
[0019] [PTL 4]WO2016 / 136933
[0020] lightning rod
[0021] [NPL 1]Venkatesan A,Tunkel AR,Bloch KC,et al.,Clin Infect Dis2013;57:1114-28
[0022] [NPL 2]Leypoldt F,Wandinger KP,Bien C,et al.,Eur Neurol Rev2013;8:31-7
[0023] [NPL 3]Hughes EG,Peng X,Gleichman AJ,et al.,J Neurosci2010;30:5866-75
[0024] [NPL 4]Mikasova L,De Rossi P,Bouchet D,et al.,Brain 2012;135:1606-21
[0025] [NPL 5]Moscato EH,Peng X,Jain A,et al.,Ann Neurol 2014;76:108-19
[0026] [NPL 6]Rosch RE,Wright S,Cooray G,et al.,Proc Natl Acad Sci USA 2018;115:E9916-25
[0027] [NPL 7]Dalmau J,Armangue T,Lancet Neurology 2019;11:1045-1057
[0028] [NPL 8]Hang HL,Zhang JH,Chen DW,et al.,Front Neurol 2020;11:852
[0029] [NPL 9]Petit-Pedrol M,Sell J,Planaguma J,et al.,Brain 2018;141:3144-59
[0030] [NPL 10] Ohkawa T, Fukata Y, Miwako Y, et al., J Neurosci2013;33:18161-74
[0031] [NPL 11] Dubey D, Pittock S, Kelly C, et al., Ann Neurol 2018;83:166-77
[0032] [NPL 12] van Sonderen A, Thijs R, Coenders E, et al., Neurology2016;87:1449-56
[0033] [NPL 13]Abboud H,Probasco J,Irani SR,et al.,J Neurol NeurosurgPsychiatry 2021.doi:10.1136 / jnnp-2020-325302
[0034] [NPL 14] Gadoth A, Pittock S, Dubey D, et al., Ann Neurol. 2017; 82:79-92 Summary of the invention
[0035] Technical issues
[0036] Current treatments for autoimmune encephalitis (AIE), such as anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis, use only off-label immunotherapies and are based on expert opinion, retrospective case series, and open-label studies. All currently available AIE treatment options, including high-dose corticosteroids and cyclophosphamide, carry significant potential safety risks. In addition, there are currently no approved therapies for anti-NMDAR encephalitis and anti-LGI1 encephalitis. Several unmet needs exist, including the frequent occurrence of long-term cognitive deficits, inadequate seizure control, and frequent reliance on high-dose corticosteroids and faster-acting but durable immunotherapies. Evidence-based treatments need to be proposed prospectively to effectively mitigate the acute and long-term consequences of these diseases.
[0037] Solution to the problem
[0038] To address the above problems, the inventors designed a phase III, randomized, double-blind (DB), placebo-controlled, multicenter basket study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of satelizumab compared with placebo in the treatment of anti-NMDAR encephalitis and anti-LGI1 encephalitis. The study showed that satelizumab addressed the above unmet needs and also confirmed the effectiveness of satelizumab in treating AIE, preventing AIE relapse and reducing the risk of AIE relapse in patients with NMDAR or LGI1 encephalitis.
[0039] The present disclosure includes, but is not limited to, the embodiments exemplarily described below.
[0040] [A1.1] A medicament for treating autoimmune encephalitis (AIE) in a subject or reducing the risk of recurrence thereof, comprising an IL-6 inhibitor as an active ingredient.
[0041] [A1.2] The drug described in A1.1, wherein the IL-6 inhibitor is an anti-IL-6 antibody or an antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0042] [A1.3] The drug described in A1.1 or A1.2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0043] [A1.4] The drug of any one of A1.1-A1.3, wherein the IL-6 inhibitor is a humanized antibody.
[0044] [A1.5] The drug described in any one of A1.1-A1.4, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
[0045] [A1.6] The drug described in A1.5, wherein the anti-IL-6 receptor antibody or its antigen-binding fragment comprises VH and VL, the VH comprises the amino acid sequence of SEQ ID NO: 1, and the VL comprises the amino acid sequence of SEQ ID NO: 2.
[0046] [A1.7] The drug described in A1.5 or A1.6, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody, which comprises a heavy chain and a light chain, the heavy chain comprises the amino acid sequence of SEQ ID NO: 3, and the light chain comprises the amino acid sequence of SEQ ID NO: 4.
[0047] [A1.8] The drug of any one of A1.5-A1.7, wherein the IL-6 inhibitor is satelizumab.
[0048] [A1.9] The drug described in any of A1.1-A1.8, which is used to delay the recurrence of autoimmune encephalitis in a subject, reduce the frequency of recurrence of autoimmune encephalitis in a subject, reduce the severity of recurrence of autoimmune encephalitis in a subject, or reduce the need for rescue therapy for recurrence of autoimmune encephalitis in a subject.
[0049] [A1.10] The drug of any one of A1.1-A1.9, wherein the subject is positive for anti-N-methyl-D aspartate receptor (NMDAR) antibody or anti-leucine-rich glioma inactivated 1 (LGI1) antibody.
[0050] [A1.11] The drug of any one of A1.1 to A1.10, wherein the autoimmune encephalitis is a disease other than Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, Hashimoto's encephalopathy, primary vasculitis of the central nervous system (CNS), and Rasmussen's encephalitis.
[0051] [A1.12] The medicament of any of A1.1-A1.11, wherein the anti-NMDAR antibody is detected in cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0052] [A1.13] The drug of any one of A1.1-A1.12, wherein the autoimmune encephalitis is anti-NMDAR encephalitis.
[0053] [A1.14] The medicament of any one of A1.1-A1.11, wherein anti-LGI1 antibodies are detected in serum or cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0054] [A1.15] The drug described in A1.14, wherein the subject experiences working memory deficits, seizures, or psychiatric symptoms suggesting involvement of the limbic system.
[0055] [A1.16] The drug of any one of A1.1-A1.11 and A1.14-A1.15, wherein the autoimmune encephalitis is anti-LGI1 encephalitis.
[0056] [A1.17] The drug of any one of A1.1-A1.16, wherein the autoimmune encephalitis is anti-NMDAR encephalitis or anti-LGI1 encephalitis.
[0057] [A1.18] The drug described in any one of A1.1-A1.17, wherein the subject is anti-caspr2, anti-IgLON5, anti-DPPX, anti-GABA A , anti-neuronal surface protein-3α, and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies were negative.
[0058] [A1.19] The drug of any one of A1.1-A1.18, wherein the subject is negative for cell surface neuronal antibodies or glial antibodies other than anti-NMDAR and anti-LGI1 antibodies.
[0059] [A1.20] The drug described in any one of A1.1-A1.19, wherein the subject (i) is anti-NMDAR antibody positive and is 12 years old or older; or (ii) is anti-LGI1 antibody positive and is 18 years old or older.
[0060] [A1.21] The drug of any one of A1.1-A1.20, wherein the subject is not receiving ongoing chronic immunosuppressive therapy.
[0061] [A1.22] The drug described in any of A1.1-A1.20, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), intravenous (IV) cyclophosphamide, oral corticosteroids (OCS), or a combination of AZA or MMF or IV cyclophosphamide and OCS.
[0062] [A1.23] The drug described in any one of A1.5-A1.22 is characterized in that the drug is used in the following manner: each time, 60 mg or 120 mg, 120 mg or 180 mg, and 180 mg or 240 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment is administered to subjects weighing less than 40 kg, 40 to 100 kg, and more than 100 kg, respectively.
[0063] [A1.24] The drug described in any one of A1.5-A1.22 is characterized in that the drug is used in the manner of administering 60 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing less than 40 kg each time.
[0064] [A1.25] The drug described in any one of A1.5-A1.22 is characterized in that the drug is used by administering 120 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing less than 40 kg each time.
[0065] [A1.26] The drug described in any one of A1.5-A1.22 is characterized in that the drug is used by administering 120 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing 40 to 100 kg each time.
[0066] [A1.27] The drug described in any one of A1.5-A1.22 is characterized in that the drug is used by administering 180 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing 40 to 100 kg each time.
[0067] [A1.28] The drug described in any one of A1.5-A1.22 is characterized in that the drug is used by administering 180 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing more than 100 kg each time.
[0068] [A1.29] The drug described in any one of A1.5-A1.22 is characterized in that the drug is used by administering 240 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing more than 100 kg each time.
[0069] [A1.30] The drug described in any one of A1.5-A1.29 is characterized in that the drug is used by subcutaneously administering the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject.
[0070] [A1.31] The drug described in any one of A1.5-A1.30 is characterized in that the drug is administered to the subject as an anti-IL-6 receptor antibody or an antigen-binding fragment thereof once every two weeks (Q2W) for a total of three times, and then once every four weeks (Q4W).
[0071] [A1.32] The drug described in any one of A1.1-A1.31, characterized in that the drug is used in combination with immunosuppressive therapy (IST).
[0072] [A1.33] The drug described in A1.32, wherein the IST is a therapy using: (i) an immunosuppressant selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide; (ii) oral corticosteroids (OCS); or (iii) a combination of (i) and (ii).
[0073] [A1.34] The drug described in A1.33, wherein the immunosuppressant comprises prednisone, prednisolone or an equivalent thereof.
[0074] [A1.35] The drug according to any one of A1.1 to A1.34, which improves the modified Rankin Scale (mRS) score.
[0075] [A1.36] The drug described in A1.35,
[0076] - Reduced time to improvement in modified Rankin Scale (mRS) score without rescue therapy
[0077] - Delayed rescue therapy
[0078] - Delayed time to freedom from seizure or status epilepticus without rescue therapy
[0079] - Improved Clinical Assessment Scale for Encephalitis (CASE) scores
[0080] - Improve the overall score of Montreal Cognitive Assessment (MOCA)
[0081] - Improvement in Rey Auditory Verbal Learning Test (RAVLT) scores in subjects with anti-LGI1 antibodies and / or
[0082] - Improves mRS scores in subjects with anti-NMDAR antibodies.
[0083] [A1.37] A drug as described in any of A1.1-A1.36, which improves a subject's score on one or more of the following: modified Rankin Scale (mRS), Clinical Assessment of Encephalitis (CASE), Montreal Cognitive Assessment (MOCA), Rey Auditory Verbal Learning Test (RAVLT), or Columbia-Suicidality Severity Rating Scale (C-SSRS).
[0084] [A1.38] A drug described in any of A1.1-A1.36, which reduces the subject's modified Rankin Scale (mRS) score, or Clinical Assessment Scale for Encephalitis (CASE) score; or improves the subject's Montreal Cognitive Assessment (MOCA) total score, or Rey Auditory Verbal Learning Test (RAVLT) score.
[0085] [A1.39] The drug according to any one of A1.1-A1.38, which is administered via a subcutaneous administration device.
[0086] [A1.40] The drug described in A1.39, wherein the subcutaneous administration device is a prefilled syringe (PFS) optionally including a needle safety device (PFS-NSD), or an autoinjector (AI).
[0087] [A2.1] A pharmaceutical composition for treating autoimmune encephalitis (AIE) in a subject or reducing the risk of recurrence thereof, comprising an IL-6 inhibitor as an active ingredient.
[0088] [A2.2] The pharmaceutical composition described in A2.1, wherein the IL-6 inhibitor is an anti-IL-6 antibody or an antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0089] [A2.3] The pharmaceutical composition described in A2.1 or A2.2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0090] [A2.4] The pharmaceutical composition of any one of A2.1-A2.3, wherein the IL-6 inhibitor is a humanized antibody.
[0091] [A2.5] The pharmaceutical composition described in any one of A2.1-A1.4, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
[0092] [A2.6] The pharmaceutical composition described in A2.5, wherein the anti-IL-6 receptor antibody or its antigen-binding fragment comprises VH and VL, the VH comprises the amino acid sequence of SEQ ID NO: 1, and the VL comprises the amino acid sequence of SEQ ID NO: 2.
[0093] [A2.7] The pharmaceutical composition described in A2.5 or A2.6, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody, which comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 3 and a light chain containing the amino acid sequence of SEQ ID NO: 4.
[0094] [A2.8] The pharmaceutical composition of any one of A2.5-A2.7, wherein the IL-6 inhibitor is satelizumab.
[0095] [A2.9] A pharmaceutical composition as described in any one of A2.1-A2.8, which is used to delay the recurrence of autoimmune encephalitis in a subject, reduce the frequency of recurrence of autoimmune encephalitis in a subject, reduce the severity of recurrence of autoimmune encephalitis in a subject, or reduce the need for rescue therapy for the recurrence of autoimmune encephalitis in a subject.
[0096] [A2.10] The pharmaceutical composition of any one of A2.1-A2.9, wherein the subject is positive for anti-N-methyl-D aspartate receptor (NMDAR) antibody or anti-leucine-rich glioma inactivated 1 (LGI1) antibody.
[0097] [A2.11] The pharmaceutical composition of any one of A2.1-A2.10, wherein the autoimmune encephalitis is a disease other than Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, Hashimoto's encephalopathy, primary vasculitis of the central nervous system (CNS), and Rasmussen encephalitis.
[0098] [A2.12] The pharmaceutical composition of any one of A2.1-A2.11, wherein the anti-NMDAR antibody is detected in cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0099] [A2.13] The pharmaceutical composition of any one of A2.1-A2.12, wherein the autoimmune encephalitis is anti-NMDAR encephalitis.
[0100] [A2.14] The pharmaceutical composition of any one of A2.1-A2.11, wherein anti-LGI1 antibodies are detected in serum or cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0101] [A2.15] The pharmaceutical composition described in A2.14, wherein the subject has experienced working memory deficits, epileptic seizures, or psychiatric symptoms indicating involvement of the limbic system.
[0102] [A2.16] The pharmaceutical composition of any of A2.1-A2.11 and A2.14-A2.15, wherein the autoimmune encephalitis is anti-LGI1 encephalitis.
[0103] [A2.17] The pharmaceutical composition of any one of A2.1-A2.16, wherein the autoimmune encephalitis is anti-NMDAR encephalitis or anti-LGI1 encephalitis.
[0104] [A2.18] A pharmaceutical composition as described in any one of A2.1-A2.17, wherein the subject is anti-caspr2, anti-IgLON5, anti-DPPX, anti-GABA A, anti-neuronal surface protein-3α, and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies were negative.
[0105] [A2.19] The pharmaceutical composition of any one of A2.1-A2.18, wherein the subject is negative for cell surface neuronal antibodies or glial antibodies other than anti-NMDAR and anti-LGI1 antibodies.
[0106] [A2.20] The pharmaceutical composition described in any one of A2.1-A2.19, wherein the subject (i) is anti-NMDAR antibody positive and is 12 years old or older; or (ii) is anti-LGI1 antibody positive and is 18 years old or older.
[0107] [A2.21] The pharmaceutical composition of any one of A2.1-A2.20, wherein the subject is not receiving ongoing chronic immunosuppressive therapy.
[0108] [A2.22] The pharmaceutical composition described in any of A2.1-A2.20, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), intravenous (IV) cyclophosphamide, oral corticosteroids (OCS), or a combination of AZA or MMF or IV cyclophosphamide and OCS.
[0109] [A2.23] The pharmaceutical composition described in any one of A2.5-A2.22 is characterized in that the pharmaceutical composition is used by administering 60 mg or 120 mg, 120 mg or 180 mg and 180 mg or 240 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to subjects weighing less than 40 kg, 40 to 100 kg and more than 100 kg, respectively.
[0110] [A2.24] The pharmaceutical composition described in any one of A2.5-A2.22 is characterized in that the pharmaceutical composition is used by administering 60 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing less than 40 kg each time.
[0111] [A2.25] The pharmaceutical composition described in any one of A2.5-A2.22 is characterized in that the pharmaceutical composition is used by administering 120 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing less than 40 kg each time.
[0112] [A2.26] The pharmaceutical composition described in any one of A2.5-A2.22 is characterized in that the pharmaceutical composition is used by administering 120 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing 40 to 100 kg each time.
[0113] [A2.27] The pharmaceutical composition described in any one of A2.5-A2.22 is characterized in that the pharmaceutical composition is used by administering 180 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing 40 to 100 kg each time.
[0114] [A2.28] The pharmaceutical composition described in any one of A2.5-A2.22 is characterized in that the pharmaceutical composition is used by administering 180 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing more than 100 kg each time.
[0115] [A2.29] The pharmaceutical composition described in any one of A2.5-A2.22 is characterized in that the pharmaceutical composition is used by administering 240 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing more than 100 kg each time.
[0116] [A2.30] The pharmaceutical composition described in any one of A2.5-A2.29 is characterized in that the pharmaceutical composition is used by subcutaneously administering the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject.
[0117] [A2.31] The pharmaceutical composition described in any one of A2.5-A2.30 is characterized in that the drug is administered to the subject as an anti-IL-6 receptor antibody or an antigen-binding fragment thereof once every two weeks (Q2W) for a total of three times, and then once every four weeks (Q4W).
[0118] [A2.32] The pharmaceutical composition described in any one of A2.1-A2.31, characterized in that the pharmaceutical composition is used in combination with immunosuppressive therapy (IST).
[0119] [A2.33] The pharmaceutical composition described in A2.32, wherein the IST is a therapy using: (i) an immunosuppressant selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide; (ii) an oral corticosteroid (OCS); or (iii) a combination of (i) and (ii).
[0120] [A2.34] The pharmaceutical composition described in A2.33, wherein the immunosuppressant comprises prednisone, prednisolone or an equivalent thereof.
[0121] [A2.35] The pharmaceutical composition of any one of A2.1-A2.34, which improves the improvement of modified Rankin Scale (mRS) score.
[0122] [A2.36] The pharmaceutical composition described in A2.35,
[0123] - Reduced time to improvement in modified Rankin Scale (mRS) score without rescue therapy
[0124] - Delayed rescue therapy
[0125] - Delay in achieving seizure freedom or status epilepticus without rescue therapy
[0126] - Improved Clinical Assessment Scale for Encephalitis (CASE) scores
[0127] - Improve the overall score of Montreal Cognitive Assessment (MOCA)
[0128] - Improvement in Rey Auditory Verbal Learning Test (RAVLT) scores in subjects with anti-LGI1 antibodies and / or
[0129] - Improves mRS scores in subjects with anti-NMDAR antibodies.
[0130] [A2.37] A pharmaceutical composition as described in any of A2.1-A2.36, which improves a subject's score on one or more of the following: modified Rankin Scale (mRS), Clinical Assessment of Encephalitis (CASE), Montreal Cognitive Assessment (MOCA), Rey Auditory Verbal Learning Test (RAVLT) or Columbia-Suicidality Severity Rating Scale (C-SSRS).
[0131] [A2.38] A pharmaceutical composition described in any one of A2.1-A2.36, which reduces the subject's modified Rankin Scale (mRS) score, or the Clinical Assessment Scale for Encephalitis (CASE) score; or improves the subject's Montreal Cognitive Assessment (MOCA) total score, or the Rey Auditory Verbal Learning Test (RAVLT) score.
[0132] [A2.39] The pharmaceutical composition of any one of A2.1-A2.38, which is administered via a subcutaneous administration device.
[0133] [A2.40] The pharmaceutical composition described in A2.39, wherein the subcutaneous administration device is a prefilled syringe (PFS) optionally including a needle safety device (PFS-NSD), or an autoinjector (AI).
[0134] [B1] Use of an IL-6 inhibitor in the preparation of a medicament for treating autoimmune encephalitis (AIE) in a subject or reducing the risk of recurrence thereof.
[0135] [B2] The use described in B1, wherein the IL-6 inhibitor is an anti-IL-6 antibody or an antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0136] [B3] The use described in B1 or B2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0137] [B4] The use according to any one of B1 to B3, wherein the IL-6 inhibitor is a humanized antibody.
[0138] [B5] The use described in any one of B1 to B4, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
[0139] [B6] The use described in B5, wherein the anti-IL-6 receptor antibody or its antigen-binding fragment comprises VH and VL, the VH comprises the amino acid sequence of SEQ ID NO: 1, and the VL comprises the amino acid sequence of SEQ ID NO: 2.
[0140] [B7] The use described in B5 or B6, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody, which comprises a heavy chain and a light chain, the heavy chain comprises the amino acid sequence of SEQ ID NO: 3, and the light chain comprises the amino acid sequence of SEQ ID NO: 4.
[0141] [B8] The use according to any one of B5-B7, wherein the IL-6 inhibitor is satelizumab.
[0142] [B9] The use described in any one of B1-B8, wherein the drug is used to delay the recurrence of autoimmune encephalitis in a subject, reduce the frequency of recurrence of autoimmune encephalitis in a subject, reduce the severity of recurrence of autoimmune encephalitis in a subject, or reduce the need for rescue therapy for recurrence of autoimmune encephalitis in a subject.
[0143] [B10] The use described in any one of B1-B9, wherein the subject is positive for anti-N-methyl-D-aspartate receptor (NMDAR) antibody or anti-leucine-rich glioma inactivated 1 (LGI1) antibody.
[0144] [B11] The use according to any one of B1 to B10, wherein the autoimmune encephalitis is a disease other than Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, Hashimoto's encephalopathy, primary vasculitis of the central nervous system (CNS) and Rasmussen encephalitis.
[0145] [B12] The use of any one of B1-B11, wherein the anti-NMDAR antibody is detected in cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0146] [B13] The use described in any one of B1-B12, wherein the autoimmune encephalitis is anti-NMDAR encephalitis.
[0147] [B14] The use of any one of B1-B11, wherein the anti-LGI1 antibodies are detected in serum or cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0148] [B15] The use described in B14, wherein the subject experiences working memory deficits, epileptic seizures, or psychiatric symptoms indicating involvement of the limbic system.
[0149] [B16] The use of any one of B1-B11 and B14-B15, wherein the autoimmune encephalitis is anti-LGI1 encephalitis.
[0150] [B17] The use described in any one of B1-B16, wherein the autoimmune encephalitis is anti-NMDAR encephalitis or anti-LGI1 encephalitis.
[0151] [B18] The use described in any one of B1-B17, wherein the subject is anti-caspr2, anti-IgLON5, anti-DPPX, anti-GABA A , anti-neuronal surface protein-3α, and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies were negative.
[0152] [B19] The use of any one of B1-B18, wherein the subject is negative for cell surface neuronal antibodies or glial antibodies other than anti-NMDAR and anti-LGI1 antibodies.
[0153] [B20] The use described in any one of B1-B19, wherein the subject is (i) anti-NMDAR antibody positive and is 12 years old or older; or (ii) anti-LGI1 antibody positive and is 18 years old or older.
[0154] [B21] The use of any one of B1-B20, wherein the subject is not receiving continuous chronic immunosuppressive therapy.
[0155] [B22] The use described in any of B1-B20, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), intravenous (IV) cyclophosphamide, oral corticosteroids (OCS), or a combination of AZA or MMF or IV cyclophosphamide and OCS.
[0156] [B23] The use described in any one of B5-B22, wherein the drug is characterized in that the drug is used by administering 60 mg or 120 mg, 120 mg or 180 mg and 180 mg or 240 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to subjects weighing less than 40 kg, 40 to 100 kg and more than 100 kg, respectively.
[0157] [B24] The use described in any one of B5-B22, wherein the drug is administered by administering 60 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing less than 40 kg per administration.
[0158] [B25] The use described in any one of B5-B22, wherein the drug is used by administering 120 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing less than 40 kg per administration.
[0159] [B26] The use described in any one of B5-B22, wherein the drug is used by administering 120 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing 40 to 100 kg per administration.
[0160] [B27] The use according to any one of B5 to B22, wherein the drug is administered by administering 180 mg of the anti-IL-6 receptor antibody or antigen-binding fragment thereof to a subject weighing 40 to 100 kg per administration.
[0161] [B28] The use according to any one of B5 to B22, wherein the drug is administered by administering 180 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing more than 100 kg per administration.
[0162] [B29] The use according to any one of B5 to B22, wherein the drug is administered by administering 240 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject weighing more than 100 kg per administration.
[0163] [B30] The use described in any one of B5-B29, wherein the drug is used by subcutaneously administering the anti-IL-6 receptor antibody or its antigen-binding fragment to a subject.
[0164] [B31] The use described in any one of B5-B30 is characterized in that the drug is administered to the subject once every two weeks (Q2W) for a total of three times, and then once every four weeks (Q4W).
[0165] [B32] The use described in any one of B1-B31, wherein the drug is characterized in that the drug is used in combination with immunosuppressive therapy (IST).
[0166] [B33] The use described in B32, wherein the IST is a therapy using: (i) an immunosuppressant selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide; (ii) oral corticosteroids (OCS); or (iii) a combination of (i) and (ii).
[0167] [B34] The use described in B33, wherein the immunosuppressant comprises prednisone, prednisolone or an equivalent thereof.
[0168] [B35] The use described in any one of B1-B34, wherein the drug improves the improvement in modified Rankin Scale (mRS) score.
[0169] [B36] The use described in B35, wherein the drug
[0170] - Reduced time to improvement in modified Rankin Scale (mRS) score without rescue therapy
[0171] -Delays the need for rescue therapy
[0172] - Delayed time to freedom from seizure or status epilepticus without rescue therapy
[0173] - Improved Clinical Assessment Scale for Encephalitis (CASE) scores
[0174] - Improve the overall score of Montreal Cognitive Assessment (MOCA)
[0175] - Improvement in Rey Auditory Verbal Learning Test (RAVLT) scores in subjects with anti-LGI1 antibodies and / or
[0176] - Improves mRS scores in subjects with anti-NMDAR antibodies.
[0177] [B37] The use described in any of B1-B36, wherein the drug improves the subject's score on one or more of the following: modified Rankin Scale (mRS), Clinical Assessment of Encephalitis (CASE), Montreal Cognitive Assessment (MOCA), Rey Auditory Verbal Learning Test (RAVLT) or Columbia-Suicidality Severity Rating Scale (C-SSRS).
[0178] [B38] The use described in any one of B1-B36, wherein the drug reduces the subject's modified Rankin Scale (mRS) score, or the Clinical Assessment Scale for Encephalitis (CASE) score; or increases the subject's Montreal Cognitive Assessment (MOCA) total score, or the Rey Auditory Verbal Learning Test (RAVLT) score.
[0179] [B39] The use according to any one of B1-B38, which is administered via a subcutaneous administration device.
[0180] [B40] The use described in B39, wherein the subcutaneous administration device is a prefilled syringe (PFS) optionally including a needle safety device (PFS-NSD), or an automatic injector (AI).
[0181] [C1] An IL-6 inhibitor for use in treating autoimmune encephalitis (AIE) in a subject or reducing the risk of recurrence thereof.
[0182] [C2] The IL-6 inhibitor for the use of C1, wherein the IL-6 inhibitor is an anti-IL-6 antibody or an antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0183] [C3] The IL-6 inhibitor for use according to C1 or C2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0184] [C4] The IL-6 inhibitor for use according to any one of C1 to C3, wherein the IL-6 inhibitor is a humanized antibody.
[0185] [C5] The IL-6 inhibitor for the use of any one of C1 to C4, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VLCDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
[0186] [C6] The IL-6 inhibitor for the use of C5, wherein the anti-IL-6 receptor antibody or its antigen-binding fragment comprises VH and VL, the VH comprises the amino acid sequence of SEQ ID NO: 1, and the VL comprises the amino acid sequence of SEQ ID NO: 2.
[0187] [C7] The IL-6 inhibitor for use of C5 or C6, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody comprising a heavy chain and a light chain, the heavy chain comprising the amino acid sequence of SEQ ID NO: 3, and the light chain comprising the amino acid sequence of SEQ ID NO: 4.
[0188] [C8] The IL-6 inhibitor for use according to any one of C5 to C7, wherein the IL-6 inhibitor is satelizumab.
[0189] [C9] The IL-6 inhibitor of any use of C1-C8, which is used to delay the recurrence of autoimmune encephalitis in a subject, reduce the frequency of recurrence of autoimmune encephalitis in a subject, reduce the severity of recurrence of autoimmune encephalitis in a subject, or reduce the need for rescue therapy for the recurrence of autoimmune encephalitis in a subject.
[0190] [C10] The IL-6 inhibitor for use according to any one of C1-C9, wherein the subject is positive for anti-N-methyl-D-aspartate receptor (NMDAR) antibody or anti-leucine-rich glioma inactivated 1 (LGI1) antibody.
[0191] [C11] The IL-6 inhibitor for use according to any one of C1 to C10, wherein the autoimmune encephalitis is a disease other than Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, Hashimoto's encephalopathy, primary vasculitis of the central nervous system (CNS), and Rasmussen encephalitis.
[0192] [C12] The IL-6 inhibitor for use according to any one of C1-C11, wherein the anti-NMDAR antibodies are detected in the cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0193] [C13] The IL-6 inhibitor for use according to any one of C1-C12, wherein the autoimmune encephalitis is anti-NMDAR encephalitis.
[0194] [C14] The IL-6 inhibitor for use according to any one of C1 to C11, wherein anti-LGI1 antibodies are detected in serum or cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0195] [C15] The IL-6 inhibitor for use of C14, wherein the subject experiences working memory deficits, epileptic seizures, or psychiatric symptoms indicative of limbic system involvement.
[0196] [C16] The IL-6 inhibitor for use according to any one of C1-C11 and C14-C15, wherein the autoimmune encephalitis is anti-LGI1 encephalitis.
[0197] [C17] The IL-6 inhibitor for use according to any one of C1-C16, wherein the autoimmune encephalitis is anti-NMDAR encephalitis or anti-LGI1 encephalitis.
[0198] [C18] The IL-6 inhibitor for use in any one of C1-C17, wherein the subject is resistant to caspr2, anti-IgLON5, anti-DPPX, anti-GABA A , anti-neuronal surface protein-3α, and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies were negative.
[0199] [C19] The IL-6 inhibitor for use according to any one of C1-C18, wherein the subject is negative for cell surface neuronal antibodies or glial antibodies other than anti-NMDAR and anti-LGI1 antibodies.
[0200] [C20] The IL-6 inhibitor for use according to any one of C1-C19, wherein the subject is (i) anti-NMDAR antibody positive and is 12 years old or older; or (ii) anti-LGI1 antibody positive and is 18 years old or older.
[0201] [C21] The IL-6 inhibitor for use according to any one of C1-C20, wherein the subject is not receiving ongoing chronic immunosuppressive therapy.
[0202] [C22] The IL-6 inhibitor for the use of any of C1-C20, wherein the subject is receiving continuous treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), intravenous (IV) cyclophosphamide, oral corticosteroids (OCS), or a combination of AZA or MMF or IV cyclophosphamide and OCS.
[0203] [C23] The IL-6 inhibitor for the use of any one of C5-C22 is characterized in that 60 mg or 120 mg, 120 mg or 180 mg and 180 mg or 240 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment are administered to subjects weighing less than 40 kg, 40 to 100 kg and more than 100 kg, respectively, per administration.
[0204] [C24] The IL-6 inhibitor for the use of any one of C5-C22, characterized in that 60 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment is administered to a subject weighing less than 40 kg per administration.
[0205] [C25] The IL-6 inhibitor for the use of any one of C5-C22, characterized in that 120 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment is administered to a subject weighing less than 40 kg per administration.
[0206] [C26] The IL-6 inhibitor for the use of any one of C5-C22, characterized in that 120 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment is administered to a subject weighing 40 to 100 kg per administration.
[0207] [C27] The IL-6 inhibitor for the use of any one of C5-C22, characterized in that 180 mg of the anti-IL-6 receptor antibody or the antigen-binding fragment thereof is administered to a subject weighing 40 to 100 kg per administration.
[0208] [C28] The IL-6 inhibitor for the use of any one of C5-C22, characterized in that 180 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment is administered to a subject weighing more than 100 kg per administration.
[0209] [C29] The IL-6 inhibitor for the use of any one of C5-C22, characterized in that 240 mg of the anti-IL-6 receptor antibody or its antigen-binding fragment is administered to a subject weighing more than 100 kg per administration.
[0210] [C30] The IL-6 inhibitor for the use according to any one of C5 to C29, characterized in that the anti-IL-6 receptor antibody or the antigen-binding fragment thereof is subcutaneously administered to the subject.
[0211] [C31] The IL-6 inhibitor for the use of any one of C5-C30 is characterized in that the anti-IL-6 receptor antibody or its antigen-binding fragment is administered to the subject once every two weeks (Q2W) for a total of three times, and then once every four weeks (Q4W).
[0212] [C32] The IL-6 inhibitor for use according to any one of C1 to C31, which is used in combination with immunosuppressive therapy (IST).
[0213] [C33] The IL-6 inhibitor for use of C32, wherein the IST is a therapy using: (i) an immunosuppressant selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide; (ii) oral corticosteroids (OCS); or (iii) a combination of (i) and (ii).
[0214] [C34] The IL-6 inhibitor for use of C33, wherein the immunosuppressant comprises prednisone, prednisolone or an equivalent thereof.
[0215] [C35] The IL-6 inhibitor for use according to any one of C1-C34, which improves the improvement in modified Rankin Scale (mRS) score.
[0216] [C36] The IL-6 inhibitor for use of C35, wherein
[0217] - Reduced time to improvement in modified Rankin Scale (mRS) score without rescue therapy
[0218] - Delayed rescue therapy
[0219] - Delayed time to freedom from seizure or status epilepticus without rescue therapy
[0220] - Improved Clinical Assessment Scale for Encephalitis (CASE) scores
[0221] - Improve the overall score of Montreal Cognitive Assessment (MOCA)
[0222] - Improvement in Rey Auditory Verbal Learning Test (RAVLT) scores in subjects with anti-LGI1 antibodies and / or
[0223] - Improves mRS scores in subjects with anti-NMDAR antibodies.
[0224] [C37] The IL-6 inhibitor for use in any one of C1-C36, which improves the subject's score on one or more of the following: modified Rankin Scale (mRS), Clinical Assessment of Encephalitis Scale (CASE), Montreal Cognitive Assessment (MOCA), Rey Auditory Verbal Learning Test (RAVLT) or Columbia-Suicidality Severity Rating Scale (C-SSRS).
[0225] [C38] The IL-6 inhibitor for use in any one of C1-C36, which reduces the subject's modified Rankin Scale (mRS) score, or Clinical Assessment Scale for Encephalitis (CASE) score; or improves the subject's Montreal Cognitive Assessment (MOCA) total score, or Rey Auditory Verbal Learning Test (RAVLT) score.
[0226] [C39] The IL-6 inhibitor for use according to any one of C1-C38, which is administered via a subcutaneous administration device.
[0227] [C40] The IL-6 inhibitor for use of C39, wherein the subcutaneous administration device is a prefilled syringe (PFS) optionally including a needle safety device (PFS-NSD), or an autoinjector (AI).
[0228] [C2.1] Satlizumab, which is used to treat anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis.
[0229] [C2.2] Satlizumab, for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 60 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) to subjects weighing less than 40 kg.
[0230] [C2.3] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 120 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) to subjects weighing less than 40 kg.
[0231] [C2.4] Satlizumab, which is used to treat anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 120 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) to subjects weighing 40 kg to 100 kg.
[0232] [C2.5] Satlizumab, which is used to treat anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 180 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) to subjects weighing 40 kg to 100 kg.
[0233] [C2.6] Satlizumab, for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 180 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) to subjects weighing more than 100 kg.
[0234] [C2.7] Satlizumab, for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 240 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) to subjects weighing more than 100 kg.
[0235] [C2.8] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein satlizumab is used in combination with azathioprine (AZA or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0236] [C2.9] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 60 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0237] [C2.10] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 120 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0238] [C2.11] Satlizumab for the treatment of anti-N-methyl-D aspartate receptor (NMDAR) encephalitis; wherein 120 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0239] [C2.12] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 180 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0240] [C2.13] Satlizumab for the treatment of anti-N-methyl-D aspartate receptor (NMDAR) encephalitis; wherein 180 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0241] [C2.14] Satlizumab for the treatment of anti-N-methyl-D aspartate receptor (NMDAR) encephalitis; wherein 240 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0242] [C2.15] Satlizumab, which is used to treat anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein satlizumab is used in combination with oral corticosteroids (OCS).
[0243] [C2.16] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 60 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satlizumab is used in combination with oral corticosteroids (OCS).
[0244] [C2.17] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 120 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satlizumab is used in combination with oral corticosteroids (OCS).
[0245] [C2.18] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 120 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satlizumab is used in combination with oral corticosteroids (OCS).
[0246] [C2.19] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 180 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satlizumab is used in combination with oral corticosteroids (OCS).
[0247] [C2.20] Satelizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 180 mg of Satelizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein Satelizumab is used in combination with oral corticosteroids (OCS).
[0248] [C2.21] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 240 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein satlizumab is used in combination with oral corticosteroids (OCS).
[0249] [C2.22] Satlizumab for use in the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein satlizumab is used in combination with (i) any of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0250] [C2.23] Satlizumab for the treatment of anti-N-methyl-D aspartate receptor (NMDAR) encephalitis; wherein 60 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0251] [C2.24] Satlizumab for the treatment of anti-N-methyl-D aspartate receptor (NMDAR) encephalitis; wherein 120 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0252] [C2.25] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 120 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0253] [C2.26] Satlizumab for the treatment of anti-N-methyl-D aspartate receptor (NMDAR) encephalitis; wherein 180 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0254] [C2.27] Satlizumab for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; wherein 180 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0255] [C2.28] Satlizumab for the treatment of anti-N-methyl-D aspartate receptor (NMDAR) encephalitis; wherein 240 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0256] [C2.29] Satlizumab, which is used to treat anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis.
[0257] [C2.30] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 60 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg.
[0258] [C2.31] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 120 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) to subjects weighing less than 40 kg.
[0259] [C2.32] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 120 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) to subjects weighing 40 kg to 100 kg.
[0260] [C2.33] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 180 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) to subjects weighing 40 kg to 100 kg.
[0261] [C2.34] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 180 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) to subjects weighing more than 100 kg.
[0262] [C2.35] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 240 mg of Satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) to subjects weighing greater than 100 kg.
[0263] [C2.36] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein satlizumab is used in combination with azathioprine (AZA or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0264] [C2.37] Satlizumab for use against leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 60 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0265] [C2.38] Satlizumab for use against leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 120 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and then once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0266] [C2.39] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 120 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0267] [C2.40] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 180 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0268] [C2.41] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 180 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0269] [C2.42] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 240 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein satlizumab is used in combination with azathioprine (AZA) or mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide.
[0270] [C2.43] Satlizumab, which is used to treat leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein Satlizumab is used in combination with oral corticosteroids (OCS).
[0271] [C2.44] Satelizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 60 mg of satelizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satelizumab is used in combination with oral corticosteroids (OCS).
[0272] [C2.45] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 120 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satlizumab is used in combination with oral corticosteroids (OCS).
[0273] [C2.46] Satelizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 120 mg of satelizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satelizumab is used in combination with oral corticosteroids (OCS).
[0274] [C2.47] Satelizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 180 mg of satelizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satelizumab is used in combination with oral corticosteroids (OCS).
[0275] [C2.48] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 180 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein satlizumab is used in combination with oral corticosteroids (OCS).
[0276] [C2.49] Satelizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 240 mg of satelizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein satelizumab is used in combination with oral corticosteroids (OCS).
[0277] [C2.50] Satlizumab for use in the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein satlizumab is used in combination with any one of (i) azathioprine (AZA), mycophenolate mofetil (MMF), and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0278] [C2.51] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 60 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0279] [C2.52] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 120 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing less than 40 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0280] [C2.53] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 120 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0281] [C2.54] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 180 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing 40 kg to 100 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0282] [C2.55] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 180 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0283] [C2.56] Satlizumab for the treatment of anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis; wherein 240 mg of satlizumab is administered subcutaneously once every two weeks (Q2W) for three times and once every four weeks (Q4W) thereafter to subjects weighing greater than 100 kg; and wherein satlizumab is used in combination with (i) any one of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide, and (ii) oral corticosteroids (OCS).
[0284] [D1] A kit for treating autoimmune encephalitis (AIE) in a subject or reducing the risk of recurrence thereof, comprising:
[0285] (1) The pharmaceutical composition of any one of A2.1-A2.40; and
[0286] (2) A package insert or label directing administration of the pharmaceutical composition to a subject.
[0287] [D2] The subcutaneous administration device is a prefilled syringe (PFS) optionally including a needle safety device (PFS-NSD), or an autoinjector (AI).
[0288] [D2] A subcutaneous administration device comprising a fixed dose of 60 mg of satelizumab in a pharmaceutically acceptable excipient.
[0289] [D3] A subcutaneous administration device comprising a fixed dose of 240 mg of satelizumab in a pharmaceutically acceptable excipient.
[0290] [D4] The subcutaneous administration device described in D2 or D3, wherein the device is a prefilled syringe (PFS) optionally including a needle safety device (PFS-NSD).
[0291] [D5] The subcutaneous administration device described in D2 or D3, wherein the device is an automatic injector (AI).
[0292] [D6] A subcutaneous administration device comprising a fixed dose of 60 mg of satelizumab in a pharmaceutically acceptable excipient, wherein the device is a prefilled syringe (PFS) including a needle safety device (PFS-NSD).
[0293] [D7] A subcutaneous administration device comprising a fixed dose of 120 mg of satelizumab in a pharmaceutically acceptable excipient, wherein the device is a prefilled syringe (PFS) including a needle safety device (PFS-NSD).
[0294] [D8] A subcutaneous administration device comprising a fixed dose of 120 mg, 180 mg, or 240 mg of satelizumab in a pharmaceutically acceptable excipient, wherein the device is an autoinjector (AI).
[0295] [E1] A method of treating a subject suffering from autoimmune encephalitis (AIE), the method comprising administering to the subject an effective amount of an IL-6 inhibitor.
[0296] [E2] The method of E1, wherein the IL-6 inhibitor is an anti-IL-6 antibody or an antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0297] [E3] The method of E1 or E2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0298] [E4] The method of any one of E1-E3, wherein the IL-6 inhibitor is a humanized antibody.
[0299] [E5] The method of any one of E1 to E4, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
[0300] [E6] The method described in E5, wherein the anti-IL-6 receptor antibody or antigen-binding fragment thereof comprises VH and VL, the VH comprises the amino acid sequence of SEQ ID NO: 1, and the VL comprises the amino acid sequence of SEQ ID NO: 2.
[0301] [E7] The method described in B5 or B6, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody comprising a heavy chain and a light chain, the heavy chain comprising the amino acid sequence of SEQ ID NO: 3, and the light chain comprising the amino acid sequence of SEQ ID NO: 4.
[0302] [E8] The method of any one of E5-E7, wherein the IL-6 inhibitor is satelizumab.
[0303] [E9] The method of any one of E1-E9, wherein the subject is positive for anti-N-methyl-D-aspartate receptor (NMDAR) antibody or anti-leucine-rich glioma inactivated 1 (LGI1) antibody.
[0304] [E10] The method of any one of E1 to E10, wherein the autoimmune encephalitis is a disease other than Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, Hashimoto's encephalopathy, primary vasculitis of the central nervous system (CNS), and Rasmussen's encephalitis.
[0305] [E11] The method of any one of E1-E10, wherein the anti-NMDAR antibodies are detected in cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0306] [E12] The method of any one of E1-E11, wherein the autoimmune encephalitis is anti-NMDAR encephalitis.
[0307] [E13] The method of any one of E1-E10, wherein the anti-LGI1 antibodies are detected in serum or cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0308] [E14] The method of E13, wherein the subject experiences working memory deficits, epileptic seizures, or psychiatric symptoms indicative of limbic system involvement.
[0309] [E15] The method of any one of E1-E10 and E13-E14, wherein the autoimmune encephalitis is anti-LGI1 encephalitis.
[0310] [E16] The method of any one of E1-E15, wherein the autoimmune encephalitis is anti-NMDAR encephalitis or anti-LGI1 encephalitis.
[0311] [E17] The method of any one of E1-E16, wherein the subject is anti-caspr2, anti-IgLON5, anti-DPPX, anti-GABA A , anti-neuronal surface protein-3α, and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies were negative.
[0312] [E18] The method of any one of E1-E17, wherein the subject is negative for cell surface neuronal antibodies or glial antibodies other than anti-NMDAR and anti-LGI1 antibodies.
[0313] [E19] The method of any one of E1-B18, wherein the subject is (i) anti-NMDAR antibody positive and is 12 years old or older; or (ii) anti-LGI1 antibody positive and is 18 years old or older.
[0314] [E20] The method of any one of E1-E19, wherein the subject is not receiving ongoing chronic immunosuppressive therapy.
[0315] [E21] The method described in any of E1-E19, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), intravenous (IV) cyclophosphamide, oral corticosteroids (OCS), or a combination of AZA or MMF or IV cyclophosphamide and OCS.
[0316] [E22] The method of any one of E5-E21, wherein
[0317] The subject is determined to have a body weight of less than 40 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 60 mg or 120 mg; or
[0318] The subject is determined to have a body weight of 40 kg to 100 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 120 mg or 180 mg; or
[0319] The subject is determined to have a body weight greater than 100 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 180 mg or 240 mg.
[0320] [E23] The method of any one of E5-E21, wherein the subject is determined to have a body weight of less than 40 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 60 mg.
[0321] [E24] The method of any one of E5-E21, wherein the subject is determined to have a body weight of less than 40 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 120 mg.
[0322] [E25] The method of any one of E5-E21, wherein the subject is determined to have a body weight of 40 to 100 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 120 mg.
[0323] [E26] The method of any one of E5-E21, wherein the subject is determined to have a body weight of 40 to 100 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 180 mg.
[0324] [E27] The method of any one of E5 to E21, wherein the subject is determined to have a body weight of 100 kg or more, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 180 mg.
[0325] [E28] The method of any one of E5 to E21, wherein the subject is determined to have a body weight of 100 kg or more, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 240 mg.
[0326] [E29] The method of any one of E5-E28, wherein the anti-IL-6 receptor antibody or antigen-binding fragment thereof is administered subcutaneously to the subject.
[0327] [E30] The method of any one of E5-E29, wherein the anti-IL-6 receptor antibody or antigen-binding fragment thereof is administered to the subject once every two weeks (Q2W) for three times, and then once every four weeks (Q4W).
[0328] [E31] The method of any one of E1-E30, wherein immunosuppressive therapy (IST) is administered to the subject together with an IL-6 inhibitor.
[0329] [E32] The method described in E31, wherein the IST comprises: (i) an immunosuppressant selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide; or (ii) an oral corticosteroid (OCS); or (iii) a combination of (i) and (ii).
[0330] [E33] The method of E32, wherein the immunosuppressant comprises prednisone, prednisolone or an equivalent thereof.
[0331] [E34] The method of any one of E1-E33, wherein administration of an IL-6 inhibitor to the subject enhances improvement in modified Rankin Scale (mRS) score.
[0332] [E35] The method of E34, wherein the IL-6 inhibitor is administered to the subject
[0333] - Reduced time to improvement in modified Rankin Scale (mRS) score without rescue therapy
[0334] - Delayed rescue therapy
[0335] - Delayed time to freedom from seizure or status epilepticus without rescue therapy
[0336] - Improved Clinical Assessment Scale for Encephalitis (CASE) scores
[0337] - Improve the overall score of Montreal Cognitive Assessment (MOCA)
[0338] - Improvement in Rey Auditory Verbal Learning Test (RAVLT) scores in subjects with anti-LGI1 antibodies and / or
[0339] - Improves mRS scores in subjects with anti-NMDAR antibodies.
[0340] [E36] The method of any one of E1-E35, wherein administration of an IL-6 inhibitor to a subject improves the subject's score on one or more of the following: modified Rankin Scale (mRS), Clinical Assessment of Encephalitis (CASE), Montreal Cognitive Assessment (MOCA), Rey Auditory Verbal Learning Test (RAVLT), or Columbia-Suicidality Severity Rating Scale (C-SSRS).
[0341] [E37] The method of any one of E1-E35, wherein administration of an IL-6 inhibitor to a subject reduces the subject's modified Rankin Scale (mRS) score, or Clinical Assessment Scale for Encephalitis (CASE) score; or increases the subject's Montreal Cognitive Assessment (MOCA) total score, or Rey Auditory Verbal Learning Test (RAVLT) score.
[0342] [E38] The method of any one of E1-E37, wherein the IL-6 inhibitor is administered via a subcutaneous administration device.
[0343] [E39] The method of E38, wherein the subcutaneous administration device is a prefilled syringe (PFS) optionally including a needle safety device (PFS-NSD), or an autoinjector (AI).
[0344] [F1] A method for reducing the risk of recurrence of autoimmune encephalitis (AIE) in a subject, the method comprising administering to the subject an effective amount of an IL-6 inhibitor.
[0345] [F2] The method of F1, wherein the IL-6 inhibitor is an anti-IL-6 antibody or an antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0346] [F3] The method of F1 or F2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0347] [F4] The method of any one of F1-F3, wherein the IL-6 inhibitor is a humanized antibody.
[0348] [F5] The method of any one of F1 to F4, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
[0349] [F6] The method described in F5, wherein the anti-IL-6 receptor antibody or antigen-binding fragment thereof comprises VH and VL, the VH comprises the amino acid sequence of SEQ ID NO: 1, and the VL comprises the amino acid sequence of SEQ ID NO: 2.
[0350] [F7] The method described in F5 or F6, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody comprising a heavy chain and a light chain, the heavy chain comprising the amino acid sequence of SEQ ID NO: 3, and the light chain comprising the amino acid sequence of SEQ ID NO: 4.
[0351] [F8] The method of any one of F5-F7, wherein the IL-6 inhibitor is satelizumab.
[0352] [F9] The method described in any of F1-F8, wherein reducing the risk of recurrence comprises delaying the recurrence of autoimmune encephalitis in the subject, reducing the frequency of recurrence of autoimmune encephalitis in the subject, reducing the severity of recurrence of autoimmune encephalitis in the subject, or reducing the need for rescue therapy for the recurrence of autoimmune encephalitis in the subject.
[0353] [F10] The method of any one of F1-F9, wherein the subject is positive for anti-N-methyl-D-aspartate receptor (NMDAR) antibody or anti-leucine-rich glioma inactivated 1 (LGI1) antibody.
[0354] [F11] The method of any one of F1-F10, wherein the autoimmune encephalitis is a disease other than Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, Hashimoto's encephalopathy, primary vasculitis of the central nervous system (CNS), and Rasmussen's encephalitis.
[0355] [F12] The method of any one of F1-F11, wherein the anti-NMDAR antibodies are detected in cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0356] [F13] The method of any one of F1-F12, wherein the autoimmune encephalitis is anti-NMDAR encephalitis.
[0357] [F14] The method of any one of F1-F11, wherein anti-LGI1 antibodies are detected in serum or cerebrospinal fluid (CSF) from the subject using a cell-based assay.
[0358] [F15] The method of F14, wherein the subject experiences working memory deficits, epileptic seizures, or psychiatric symptoms indicative of limbic system involvement.
[0359] [F16] The method of any one of F1-F11 and F14-F15, wherein the autoimmune encephalitis is anti-LGI1 encephalitis.
[0360] [F17] The method of any one of F1-F16, wherein the autoimmune encephalitis is anti-NMDAR encephalitis or anti-LGI1 encephalitis.
[0361] [F18] The method of any one of F1-F17, wherein the subject is anti-caspr2, anti-IgLON5, anti-DPPX, anti-GABA A , anti-neuronal surface protein-3α, and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies were negative.
[0362] [F19] The method of any one of F1-F18, wherein the subject is negative for cell surface neuronal antibodies or glial antibodies other than anti-NMDAR and anti-LGI1 antibodies.
[0363] [F20] The method described in any one of F1-F19, wherein the subject is (i) anti-NMDAR antibody positive and is 12 years old or older; or (ii) anti-LGI1 antibody positive and is 18 years old or older.
[0364] [F21] The method of any one of F1-F20, wherein the subject is not receiving ongoing chronic immunosuppressive therapy.
[0365] [F22] The method described in any of F1-F21, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), intravenous (IV) cyclophosphamide, oral corticosteroids (OCS), or a combination of AZA or MMF or IV cyclophosphamide and OCS.
[0366] [F23] The method of any one of F5-F22, wherein
[0367] The subject is determined to have a body weight of less than 40 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 60 mg or 120 mg; or
[0368] The subject is determined to have a body weight of 40 kg to 100 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 120 mg or 180 mg; or
[0369] The subject is determined to have a body weight greater than 100 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 180 mg or 240 mg.
[0370] [F24] The method of any one of F5-F22, wherein the subject is determined to have a body weight of less than 40 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 60 mg.
[0371] [F25] The method of any one of F5-F22, wherein the subject is determined to have a body weight of less than 40 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 120 mg.
[0372] [F26] The method of any one of F5-F22, wherein the subject is determined to have a body weight of 40 to 100 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 120 mg.
[0373] [F27] The method of any one of F5-F22, wherein the subject is determined to have a body weight of 40 to 100 kg, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 180 mg.
[0374] [F28] The method of any one of F5 to F22, wherein the subject is determined to have a body weight of 100 kg or more, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 180 mg.
[0375] [F29] The method of any one of F5 to F22, wherein the subject is determined to have a body weight of 100 kg or more, and the amount of the anti-IL-6 receptor antibody or antigen-binding fragment thereof administered to the subject in each administration is 240 mg.
[0376] [F30] The method of any one of F5-F29, wherein the anti-IL-6 receptor antibody or antigen-binding fragment thereof is administered subcutaneously to the subject.
[0377] [F31] The method of any one of F5-F30, wherein the anti-IL-6 receptor antibody or antigen-binding fragment thereof is administered to the subject once every two weeks (Q2W) for a total of three times, and then once every four weeks (Q4W).
[0378] [F32] The method of any one of F1-F31, wherein immunosuppressive therapy (IST) is administered to the subject together with an IL-6 inhibitor.
[0379] [F33] The method described in F32, wherein the IST comprises: (i) an immunosuppressant selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF) and intravenous (IV) cyclophosphamide; (ii) an oral corticosteroid (OCS); or (iii) a combination of (i) and (ii).
[0380] [F34] The method of F33, wherein the immunosuppressant comprises prednisone, prednisolone or an equivalent thereof.
[0381] [F35] The method described in any of F1-F34, wherein administration of an IL-6 inhibitor to the subject improves the improvement in modified Rankin Scale (mRS) score.
[0382] [F36] The method of E35, wherein the IL-6 inhibitor is administered to the subject
[0383] - Reduced time to improvement in modified Rankin Scale (mRS) score without rescue therapy
[0384] -Delays the need for rescue therapy
[0385] - Delayed time to freedom from seizure or status epilepticus without rescue therapy
[0386] - Improved Clinical Assessment Scale for Encephalitis (CASE) scores
[0387] - Improve the overall score of Montreal Cognitive Assessment (MOCA)
[0388] - Improvement in Rey Auditory Verbal Learning Test (RAVLT) scores in subjects with anti-LGI1 antibodies and / or
[0389] - Improves mRS scores in subjects with anti-NMDAR antibodies.
[0390] [F37] The method described in any of F1-F36, wherein administration of an IL-6 inhibitor to a subject improves the subject's score on one or more of the following: modified Rankin Scale (mRS), Clinical Assessment of Encephalitis (CASE), Montreal Cognitive Assessment (MOCA), Rey Auditory Verbal Learning Test (RAVLT), or Columbia-Suicidality Severity Rating Scale (C-SSRS).
[0391] [F38] The method described in any one of F1-F36, wherein administration of an IL-6 inhibitor to a subject reduces the subject's modified Rankin Scale (mRS) score, or Clinical Assessment Scale for Encephalitis (CASE) score; or increases the subject's Montreal Cognitive Assessment (MOCA) total score, or Rey Auditory Verbal Learning Test (RAVLT) score.
[0392] [F39] The method of any one of E1-E38, wherein the IL-6 inhibitor is administered via a subcutaneous administration device.
[0393] [F40] The method described in E39, wherein the subcutaneous administration device is a prefilled syringe (PFS) optionally including a needle safety device (PFS-NSD), or an autoinjector (AI).
[0394] Advantageous Effects of the Invention
[0395] The present invention can provide a drug (pharmaceutical composition) containing satelizumab, which is used for treating, preventing, preventing recurrence, or reducing the risk of recurrence of autoimmune encephalitis (such as anti-NMDAR encephalitis and anti-LGI1 encephalitis). BRIEF DESCRIPTION OF THE DRAWINGS
[0396] [ Figure 1 ] Figure 1 The primary treatment period of the study protocol for the Phase III, randomized, double-blind, placebo-controlled, multicenter basket study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satelizumab in patients with anti-N-methyl-D-aspartate receptor (NMDAR) and anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis is shown. AIE = autoimmune encephalitis; LGI1 = leucine-rich glioma inactivated 1; NMDAR = N-methyl-D-aspartate receptor; PK = pharmacokinetics; Q4W = every 4 weeks; R = randomized. Note: Week 0 baseline assessments will be performed prior to dosing. The specific dose of satelizumab (or matching placebo) will depend on the individual participant's body weight as follows: less than 40 kg: 60 mg or 120 mg Q4W; between 40 and 100 kg: 120 mg or 180 mg Q4W; more than 100 kg: 180 mg or 240 mg Q4W.
[0397] [ Figure 2 ] Figure 2 The dependence of steady-state exposure parameters and receptor occupancy on body weight after 60 mg (less than 40 kg), 120 mg (between 40 and 100 kg), or 180 mg (over 100 kg) Q4W dosing is shown. max , C trough and predicted values of RO. The simulation is based on 2000 individuals. Points are simulated data assuming that the proportion of ADA-positive participants is similar to that observed in the NMOSD study. ADA were not considered to be present for body weight < 40 kg. Horizontal dashed lines are added as reference. ADA = anti-drug antibodies; Cmax = maximum observed concentration; Ctr = steady-state concentration at the end of the dosing interval; NMOSD = neuromyelitis optica spectrum disorder; RO = receptor occupancy; Q4W = every 4 weeks. DETAILED DESCRIPTION
[0398] The present invention relates to a drug (pharmaceutical composition) for treating autoimmune encephalitis (AIE) in a subject or reducing the risk of recurrence of autoimmune encephalitis (AIE), wherein the autoimmune encephalitis includes but is not limited to anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivation 1 (LGI1) encephalitis, and the drug (pharmaceutical composition) comprises an IL-6 inhibitor as an active ingredient. Recurrence is defined as a new clinical attack (the appearance of new or worsening acute symptoms and clinical signs of AIE, for example, one month after the last attack).
[0399] On the other hand, the present invention also relates to the use of an IL-6 inhibitor in the preparation of a medicament for treating autoimmune encephalitis (AIE) in a subject or reducing the risk of recurrence of autoimmune encephalitis (AIE) in a subject, wherein the autoimmune encephalitis includes but is not limited to anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis.
[0400] In another aspect, the present invention relates to an IL-6 inhibitor for treating autoimmune encephalitis (AIE) in a subject or reducing the risk of recurrence of autoimmune encephalitis (AIE) in a subject, wherein the autoimmune encephalitis includes but is not limited to anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis.
[0401] In addition, the present invention also relates to a kit for treating autoimmune encephalitis (AIE) in a subject or reducing the risk of recurrence of autoimmune encephalitis (AIE) in a subject, comprising: a pharmaceutical composition containing an IL-6 inhibitor, and a package insert or label for guiding the administration of the pharmaceutical composition to the subject, wherein the autoimmune encephalitis includes but is not limited to anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis.
[0402] In addition, the present invention also relates to a method for treating a subject suffering from autoimmune encephalitis (AIE) or reducing the risk of recurrence of autoimmune encephalitis (AIE) in a subject, the method comprising administering to the subject an effective amount of an IL-6 inhibitor, wherein the autoimmune encephalitis includes but is not limited to anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis.
[0403] The "IL-6 inhibitor" disclosed herein is a substance that blocks the signal transduction of IL-6 and inhibits the biological activity of IL-6. The IL-6 inhibitor is preferably a substance that inhibits the binding of IL-6 to the IL-6 receptor and / or the binding of the IL-6 / IL-6 receptor complex to gp130. Examples of IL-6 inhibitors disclosed herein include, but are not limited to, anti-IL-6 antibodies or antigen-binding fragments thereof, anti-IL-6 receptor antibodies or antigen-binding fragments thereof, anti-gp130 antibodies or antigen-binding fragments thereof, IL-6 variants, soluble IL-6 receptor variants, or partial peptides of IL-6 or IL-6 receptor, and low molecular weight substances that exhibit similar activities. Examples of IL-6 inhibitors disclosed herein may preferably be anti-IL-6 antibodies or antigen-binding fragments thereof, or anti-IL-6 receptor antibodies or antigen-binding fragments thereof, more preferably anti-IL-6 receptor antibodies or antigen-binding fragments thereof, optionally humanized antibodies.
[0404] In some embodiments of the present disclosure, the IL-6 inhibitor is an anti-IL-6 receptor antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10. In certain embodiments of the present disclosure, the anti-IL-6 receptor antibody or an antigen-binding fragment thereof comprises: a VH comprising the amino acid sequence of SEQ ID NO: 1, and a VL comprising the amino acid sequence of SEQ ID NO: 2. In certain embodiments of the present disclosure, the IL-6 inhibitor is an anti-IL-6 receptor antibody, which comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO: 3, and a light chain comprising the amino acid sequence of SEQ ID NO: 4. In certain embodiments of the present disclosure, the IL-6 inhibitor is Satlizumab. In some embodiments of the present disclosure, the term "Satlizumab" is an anti-IL-6 receptor antibody comprising a heavy chain CDR1 containing an amino acid sequence of SEQ ID NO: 5, a heavy chain CDR2 containing an amino acid sequence of SEQ ID NO: 6, a heavy chain CDR3 containing an amino acid sequence of SEQ ID NO: 7, a light chain CDR1 containing an amino acid sequence of SEQ ID NO: 8, a light chain CDR2 containing an amino acid sequence of SEQ ID NO: 9, and a light chain CDR3 containing an amino acid sequence of SEQ ID NO: 10; preferably comprising a heavy chain variable region containing an amino acid sequence of SEQ ID NO: 1 and a light chain variable region containing an amino acid sequence of SEQ ID NO: 2; and most preferably comprising a heavy chain containing an amino acid sequence of SEQ ID NO: 3 and a light chain containing an amino acid sequence of SEQ ID NO: 4.
[0405] In certain embodiments of the present disclosure, autoimmune encephalitis (AIE) includes diseases associated with identifiable etiological drivers (usually tumors), as well as diseases that are considered idiopathic. In paraneoplastic immune-mediated encephalitis syndromes, these may be associated with antibodies against intracellular neuronal proteins (tumor neuronal proteins, such as anti-Hu). On the one hand, AIE is described by identifying antibodies against neuronal cell surface and synaptic proteins, such as Hu (ANNA1), Ma2, GAD, N-terminal enolase (NAE), NMDA receptors, AMPA receptors, GABA A Receptors, GABA BReceptor, mGluR5, dopamine D2 receptor, anti-leucine-rich glioma inactivated 1 (LGI1), CASPR2 and DPPX (Graus et al., Lancet Neurol., 15, 391-404, 2016; Lancaster et al., Neurology, 77, 179-189, 2011), these antibodies are considered to be directly pathogenic for AIE. The identification of these autoantibodies may help to describe a population that is better responsive to the present invention. In the present disclosure, AIE includes any AIE subtype in which one or more autoantibodies are considered to be one of the pathogenic causes, and anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis represent the two most common and best characterized AIE (Leypoldt F, Wandinger KP, Bien C et al., Eur Neurol Rev 2013; 8: 31-7). In one aspect, the AIE in the present disclosure also includes Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, Hashimoto's encephalopathy, primary vasculitis of the central nervous system (CNS), and Rasmussen's encephalitis. In the present disclosure, anti-NMDAR encephalitis and anti-LGI1 encephalitis are described as more specific embodiments.
[0406] In the present disclosure, a "subject" may be referred to as a "patient" who suffers from the above-mentioned autoimmune encephalitis (AIE), such as anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis. In one aspect, the subject is positive for anti-N-methyl-D-aspartate receptor (NMDAR) antibodies or anti-leucine-rich glioma inactivated 1 (LGI1) antibodies. In one aspect, a cell-based assay is used to detect whether the subject is positive for anti-NMDAR or anti-LGI1 in the cerebrospinal fluid (CSF) from the subject. In one aspect, a subject with anti-NMDAR or LGI1 encephalitis is positive for anti-caspr2, anti-IgLON5, anti-DPPX, anti-GABA AIn one aspect, the subject with anti-NMDAR or LGI1 encephalitis has received, not received, is receiving or is not receiving chronic immunosuppressive therapy (IST). In one aspect, the subject with anti-NMDAR or LGI1 encephalitis has received, not received, is receiving or is not receiving a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), intravenous (IV) cyclophosphamide, oral corticosteroids (OCS), or a combination of AZA or MMF or IV cyclophosphamide and OCS. In one aspect, the subject with anti-NMDAR or LGI1 encephalitis is (i) anti-NMDAR antibody positive and is 12 years of age or older; or (ii) anti-LGI1 antibody positive and is 18 years of age or older.
[0407] In certain embodiments, the medicament or pharmaceutical composition of the present invention is used in combination with immunosuppressive therapy (IST). In certain embodiments, the IST is one or more immunosuppressants selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF), and intravenous (IV) cyclophosphamide; (ii) oral corticosteroids (OCS); or (iii) a combination of (i) and (ii).
[0408] In certain embodiments, the medicament or pharmaceutical composition of the present invention can delay the time from the administration of the IL-6 inhibitor to the first occurrence of autoimmune encephalitis (AIE) recurrence, including but not limited to anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and anti-leucine-rich glioma inactivation 1 (LGI1) encephalitis. In certain embodiments, the medicament or pharmaceutical composition of the present invention can further reduce one or more of the following:
[0409] (a) Relapse rate of autoimmune encephalitis (AIE);
[0410] (b) the incidence of active lesions on neuroaxial MRI;
[0411] (c) the proportion of subjects who received rescue therapy; or
[0412] (d) Hospitalization rate.
[0413] In the present disclosure, the term "treatment" is used to mean that even if complete remission of AIE is not achieved, relieving or improving symptoms to a level that can maintain minimal manifestations (MM), or maintaining such a state, is also included in the "treatment" of AIE.
[0414] In the present disclosure, the efficacy, safety, pharmacokinetics and / or pharmacodynamics of IL-6 inhibitors (e.g., satelizumab) for treating AIE can be evaluated based on one or more aspects and / or scores as described below.
[0415] i. Improvement in modified Rankin Scale (mRS) score.
[0416] ii. Reduce the time to achieve improvement in modified Rankin Scale (mRS) score without the use of rescue therapy.
[0417] iii. Delay in the timing of rescue therapy.
[0418] iv. Delay in freedom from seizure or status epilepticus without the use of rescue therapy.
[0419] v. Improve the Clinical Assessment Scale for Encephalitis (CASE) score.
[0420] vi. Improve the total score of Montreal Cognitive Assessment (MOCA).
[0421] vii. Improving Rey Auditory Verbal Learning Test (RAVLT) scores in subjects with anti-LGI1 antibodies.
[0422] viii. Improving mRS scores in subjects with anti-NMDAR antibodies.
[0423] viii. Improvement of the Modified Fatigue Impact Scale (MFIS).
[0424] ix. Improve the Montreal Cognitive Assessment (MOCA).
[0425] X. Improvement of the Rey Auditory Verbal Learning Test (RAVLT).
[0426] xi. Improve EQ-5D-5L.
[0427] xii. Improvement of Columbia-Suicide Severity Rating Scale (C-SSRS).
[0428] Xiii. Improve the Beck Depression Inventory (BDI II).
[0429] There is no particular limitation on the given time period for evaluating the efficacy of the present invention (e.g., administering the drug or pharmaceutical composition of the present invention), and includes 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks, 48 weeks, 1 year, 2 years, 3 years, 4 years, and 5 years, and the time period may be shorter or longer than the exemplified time periods.
[0430] In the present invention, subjects (e.g., patients) with autoimmune encephalitis (AIE) can receive treatment (e.g., drugs, pharmaceutical compositions, methods, etc.) of the present invention, for example, once every two weeks (Q2W), three times (i.e., at time zero and at weeks 2 and 4), and once every four weeks (Q4W) thereafter. In some embodiments, subjects (e.g., patients) can receive the anti-IL-6 receptor antibody (e.g., satelizumab) or an antigen-binding fragment thereof contained in the drug or composition of the present invention by subcutaneous administration.
[0431] In addition to the treatment of AIE of the subject of the present invention, the present invention is also used to reduce the recurrence risk of recurrent AIE of an individual. In the present invention, reducing the risk of recurrence includes but is not limited to delaying the recurrence of AIE, reducing the frequency of AIE recurrence, or reducing the severity of AIE recurrence, or reducing the need for rescue therapy for AIE recurrence.
[0432] The anti-IL-6 receptor antibody or antigen-binding fragment thereof used in the present invention binds to the IL-6 receptor, inhibits the binding of IL-6 to the IL-6 receptor, blocks the signal transduction of IL-6, and inhibits the biological activity of IL-6.
[0433] The anti-IL-6 receptor antibody used in the present invention can be obtained by known methods. In particular, the anti-IL-6 receptor antibody used in the present invention is preferably a monoclonal antibody derived from mammals. Monoclonal antibodies derived from mammals include antibodies produced by hybridomas and antibodies produced by hosts transformed with expression vectors containing antibody genes using genetic engineering methods.
[0434] In the present invention, preferred examples of “IL-6 receptor antibodies” include: humanized anti-IL-6 receptor antibodies produced by modifying the variable region and constant region of tocilizumab, specifically: an antibody comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
[0435] More preferred antibodies in the present invention include: antibodies comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. More preferred are antibodies comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 3 (heavy chain of Satlizumab (common name); SA237 (private name)) and a light chain comprising the amino acid sequence of SEQ ID NO: 4 (light chain of Satlizumab). Satlizumab (private name: SA237) is particularly preferred.
[0436] Satlizumab has obtained government marketing authorization in several countries including Japan, the United States, and Europe for the indication of "preventing relapses of neuromyelitis optica spectrum disorders (including neuromyelitis optica)". The safety profile determined in the international joint Phase III clinical trials (SA-307JG / BN40898 study and SA-309JG / BN40900 study) for the patient population with neuromyelitis optica spectrum disorders (NMOSD) and / or neuromyelitis optica (NMO) was mostly good. No deaths were reported. The percentage of patients with serious adverse events in the satlizumab group was roughly the same as that in the placebo group. There was no significant difference between the two groups in the frequency of adverse events leading to interruption of the trial drug, or the frequency of adverse events leading to discontinuation of the trial drug. The safety profile was similar between the SA-309JG study (single drug testing) and the SA-307JG study (combination testing with pre-existing therapies (oral steroids and / or immunosuppressants)).
[0437] Such antibodies can be obtained according to the methods described in WO2010 / 035769, WO2010 / 107108, WO2010 / 106812, etc. Specifically, based on the sequence of the above-mentioned IL-6 receptor antibody, the antibody can be produced using gene recombination techniques known to those skilled in the art (for example, see Borrebaeck CAK and Larrick JW, THERAPEUTIC MONOCLONALANTIBODIES, published in the UK by MACMILLAN PUBLISHERS LTD, 1990). Recombinant antibodies can be obtained by cloning DNA encoding the antibody from a hybridoma or an antibody-producing cell (such as an antibody-producing sensitized lymphocyte), inserting the DNA into an appropriate vector, and introducing the vector into a host (host cell) to produce the antibody.
[0438] Such antibodies can be separated and purified by separation and purification methods commonly used for antibody purification, but are not limited thereto. For example, antibodies can be separated and purified by appropriately selecting and combining methods such as column chromatography, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization, and the like.
[0439] The antibody used in the present invention can be a conjugate antibody bound to various molecules such as polyethylene glycol (PEG), radioactive substances and toxins. Such a conjugate antibody can be obtained by chemically modifying the obtained antibody. Methods for antibody modification have been established in the field. Therefore, the term "antibody" in the present invention includes such a conjugate antibody.
[0440] The antibody used in the present invention may be an antibody fragment (also referred to as an antigen-binding fragment of an antibody) or a modified product thereof, as long as it can be appropriately used in the present invention. For example, antibody fragments include Fab, F(ab')2, Fv and single-chain Fv (scFv), in which the Fv of the H chain and the L chain are connected by an appropriate linker.
[0441] Specifically, antibody fragments are produced by treating antibodies with an enzyme such as papain or pepsin, or by constructing genes encoding these antibody fragments and introducing them into expression vectors, which are then expressed in appropriate host cells (see, e.g., Co, MS et al., J. Immunol. (1994) 152, 2968-2976; Better, M. and Horwitz, AH, Methods in Enzymology (1989) 178, 476-496; Plueckthun, A. and Skerra, A., Methods in Enzymology (1989) 178, 497-515; Lamoyi, E., Methods in Enzymology (1989) 121, 652-663; Rousseaux, J. et al., Methods in Enzymology (1989) 123, 657-664). Enzymology (1989) 121, 663-666; and Bird, RE et al., TIBTECH (1991) 9, 132-137).
[0442] scFv can be obtained by connecting the H chain V region and the L chain V region of an antibody. In the scFv, the H chain V region and the L chain V region are connected by a linker, preferably by a peptide linker (Huston, JS et al., Proc. Natl. Acad. Sci. USA (1988) 85, 5879-5883). The V regions of the H and L chains in the scFv can be derived from any of the above antibodies. The peptide linker used to connect the V region includes, for example, any single-chain peptide consisting of 12 to 19 amino acid residues.
[0443] The DNA encoding scFv can be obtained by the following method: using the DNA encoding the H chain or the H chain V region and the DNA encoding the L chain or the L chain V region of the above-mentioned antibody as templates, using a primer pair that defines the end of the DNA portion encoding the desired amino acid sequence, the DNA portion encoding the desired amino acid sequence in the template sequence is amplified by PCR, and then using a DNA encoding the peptide linker portion and a primer pair that defines both ends of the linker to further amplify the amplified DNA portion so that it can be connected to each of the H chain and the L chain.
[0444] Once the DNA encoding scFv is prepared, an expression vector comprising the DNA and a host transformed with the expression vector can be obtained according to conventional methods. In addition, by using the host, scFv can be obtained according to conventional methods.
[0445] Similar to the above, antibody fragments can be produced by obtaining their genes, expressing them, and then using a host.
[0446] In the present invention, "as an active ingredient" means that the ingredient is contained in the pharmaceutical composition as the main active ingredient, and unless otherwise specified, its content is not limited as long as the antibody or antigen-binding fragment thereof used in the present invention is included as a pharmaceutical ingredient.
[0447] The dosage of the anti-IL-6 receptor antibody or antigen-binding fragment thereof contained in the medicine or composition of the present invention is not particularly limited, and examples include 50 to 800 mg of antibody per administration, preferably 60 to 240 mg of antibody, and more preferably 60 mg, 120 mg, 180 mg or 240 mg of antibody per administration. The dosage of the anti-IL-6 receptor antibody or antigen-binding fragment thereof contained in the medicine or composition of the present invention may vary according to the patient's weight. In certain embodiments of the present invention, for subjects weighing less than 40 kg, the appropriate dose of the anti-IL-6 receptor antibody or antigen-binding fragment is 60 mg or 120 mg; for subjects weighing between 40 kg and 100 kg, the appropriate dose is 120 mg or 180 mg; for subjects weighing more than 100 kg, the appropriate dose is 180 mg or 240 mg. The medicine or composition comprising the anti-IL-6 receptor antibody or antigen-binding fragment thereof of the present invention is administered to the subject by any route, including but not limited to subcutaneous, intravenous, intramuscular and infusion. The preferred embodiment is subcutaneous administration.
[0448] In certain embodiments of the present invention, two or more consecutive doses of an anti-IL-6 receptor antibody or an antigen-binding fragment thereof contained in a medicament or composition of the present invention are administered to a subject in an initial phase, wherein the doses administered in the initial phase are separated by a first dosing interval (also referred to as a dosing interval shorter than a conventional dosing interval), such as 20 weeks, 8 weeks, 4 weeks, or two weeks; after the final dose of the initial phase is administered, a second dosing interval longer than the first dosing interval is waited, and then a dose of an anti-IL-6 receptor antibody or an antigen-binding fragment thereof contained in a medicament or composition of the present invention is administered to the human patient, wherein a plurality of consecutive doses are optionally administered after the final dose of the initial phase and are separated by a second dosing interval (also referred to as a "conventional dosing interval"), which is not particularly limited except that it is longer than the first dosing interval. Examples of the second dosing interval include 1 day to 24 weeks, preferably 2 weeks to 8 weeks, more preferably 3 to 5 weeks, and even more preferably 4 weeks).
[0449] In certain embodiments of the present invention, the anti-IL-6 receptor antibody or antigen-binding fragment thereof contained in the medicament or composition of the present invention is administered to a subject once every two weeks (Q2W) for a total of three times, and then once every four weeks (Q4W).
[0450] The preferred administration schedule of the anti-IL-6 receptor antibody or antigen-binding fragment thereof contained in the medicament or composition of the present invention can be adjusted by, for example, appropriately extending the administration interval by monitoring the disease condition and changes in blood test values.
[0451] The present invention also provides an article for use in the method of the present invention, such as a kit, a device, etc., which comprises a pharmaceutical composition or a medicament of the present invention. The pharmaceutical composition or medicament of the present invention comprises an IL-6 inhibitor as described herein. The article can be packaged together with an additional pharmaceutically acceptable carrier or medium, or instructions for describing how to use the kit, etc.
[0452] In one embodiment, the article comprises a container and a label on the container or a package insert associated with the container. Suitable containers include, for example, bottles, vials, syringes (including prefilled syringes and auto-injectors), IV solution bags, etc. The container can be made of a variety of materials such as glass or plastic. In one embodiment, the container holds a composition that is effective in treating, preventing and / or diagnosing a condition by itself or in combination with another composition, and can have a sterile entrance (for example, the container can be a syringe, an auto-injector, an intravenous fluid bag, or a vial with a stopper that can be pierced by a hypodermic needle). At least one active ingredient in the composition is an IL-6 inhibitor, preferably an anti-IL-6 receptor antibody, more preferably Satlizumab as described in the present disclosure.
[0453] In one embodiment, the device of the product of the present invention as described above can be a prefilled syringe optionally including a needle safety device (PFS-NSD) for injection via any route of administration (e.g., intravenous, subcutaneous, etc.), the syringe containing a fixed dose of IL-6 inhibitor in a pharmaceutically acceptable excipient, preferably an anti-IL-6 receptor antibody, more preferably the Satlizumab described in the present disclosure. In another embodiment, the device can be an automatic injector for subcutaneous administration, which contains a fixed dose of IL-6 inhibitor in a pharmaceutically acceptable excipient, preferably an anti-IL-6 receptor antibody, more preferably the Satlizumab described in the present disclosure. In certain embodiments, the device is a subcutaneous administration device such as a prefilled syringe (PFS) and an automatic injector (AI), which can contain 60 mg, 120 mg, 180 mg or 240 mg of Satlizumab. In one embodiment, the subcutaneous administration device is a pre-filled syringe comprising a needle safety device (PFS-NSD), which includes 60mg (e.g., 60mg / mL) of Satlizumab, for delivering 60mg or 180mg doses to a subject. In one embodiment, the subcutaneous administration device is a pre-filled syringe comprising a needle safety device (PFS-NSD), which includes 120mg (e.g., 60mg / 0.5mL) of Satlizumab, for delivering 120mg, 180mg, or 240mg doses to a subject. In other embodiments, the subcutaneous administration device is an automatic injector (AI) comprising 120mg, 180mg, or 240mg of Satlizumab.
[0454] In the present invention, the label or package insert indicates that the pharmaceutical composition or drug is used to treat the selected condition. In addition, the article may include (a) a first container containing a composition, wherein the composition includes an IL-6 inhibitor, preferably an anti-IL-6 receptor antibody, more preferably Satlizumab as described above; and (b) a second container containing a composition, wherein the composition includes another therapeutic agent. The article in this embodiment of the present invention may further include a package insert, which indicates that the composition can be used to treat a specific condition. Alternatively or additionally, the article may further include a second (or third) container, which contains a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials required from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.
[0455] Packaging Insert
[0456] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications, and / or warnings concerning the use of such therapeutic products.
[0457] The pharmaceutical composition or medicine of the present invention can be prepared to produce lyophilized preparations or solution preparations by mixing (if necessary) suitable pharmaceutically acceptable carriers, vehicles, etc. Suitable pharmaceutically acceptable carriers and vehicles include, for example, sterile water, physiological saline, stabilizers, excipients, antioxidants (e.g., ascorbic acid), buffers (e.g., phosphates, citrates, histidine and other organic acids), preservatives, surfactants (e.g., PEG and Tween), chelating agents (e.g., EDTA) and adhesives. Other low molecular weight polypeptides, proteins (e.g., serum albumin, gelatin and immunoglobulins), amino acids (e.g., glycine, glutamine, asparagine, glutamic acid, aspartic acid, methionine, arginine and lysine), sugars and carbohydrates (e.g., polysaccharides and monosaccharides) and sugar alcohols (e.g., mannitol and sorbitol) may also be included in the preparation. When preparing aqueous solutions for injection, physiological saline and isotonic solutions can be used, which include glucose and other adjuvants, such as D-sorbitol, D-mannose, D-mannitol and sodium chloride; and suitable solubilizers can be used in combination, such as alcohols (e.g., ethanol), polyols (such as propylene glycol and PEG) and nonionic surfactants (such as polysorbate 80, polysorbate 20, poloxamer 188 and HCO-50). By mixing hyaluronidase into the preparation, a larger liquid volume can be administered subcutaneously (Expert Opin. Drug Deliv. 2007 Jul; 4 (4): 427-40). In addition, the syringe can be pre-filled with the pharmaceutical composition of the present invention. The solution preparation can be prepared according to the method described in WO2011 / 090088.
[0458] If necessary, the pharmaceutical composition or drug of the present invention can be encapsulated in a microcapsule (e.g., microcapsules made of hydroxymethylcellulose, gelatin and poly(methyl methacrylate)), or incorporated into a colloidal drug delivery system (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) (e.g., see "Remington's Pharmaceutical Science 16th Edition", Oslo Ed. (1980)). Methods for preparing pharmaceutical preparations as controlled release pharmaceutical preparations are also known, and such methods can be applied to the pharmaceutical composition of the present invention (Langer et al., J. Biomed. Mater. Res. 15: 267-277 (1981); Langer, Chemtech. 12: 98-105 (1982); U.S. Pat. No. 3,773,919; European Patent Application Publication No. EP 58,481; Sidman et al., Biopolymers 22: 547-556 (1983); and EP 133,988).
[0459] The anti-IL-6 receptor antibody or antigen-binding fragment thereof contained in the medicament or composition of the present invention can be administered to the patient by any appropriate route. For example, it can be administered intravenously (by push injection or continuous infusion), intramuscularly, intraperitoneally, intracerebrospinal, transdermally, subcutaneously, intraarticularly, sublingually, intrasynovially, orally, by inhalation, topically or externally to the patient for a period of time. Preferably, it is administered intravenously or subcutaneously. In certain embodiments of the present invention, the anti-IL-6 receptor antibody or antigen-binding fragment thereof contained in the medicament or composition of the present invention is administered subcutaneously to the subject.
[0460] All prior art references cited herein are incorporated into this specification by reference.
[0461] Example
[0462] Hereinafter, the present invention will be specifically described with reference to Examples, but it should not be construed as being limited thereto.
[0463] Example 1: Preparation of Satlizumab (SA237)
[0464] According to the description of patent document WO 2010 / 035769, an antibody with the general name of Satlizumab (private name SA237) was prepared, which is an IL-6 receptor antibody described in the patent document, comprising a heavy chain having an amino acid sequence of SEQ ID NO: 26 (SEQ ID NO: 3 in the present specification) and a light chain having an amino acid sequence of SEQ ID NO: 29 (SEQ ID NO: 4 in the present specification). The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 2. Using the prepared antibody, a subcutaneous administration preparation was prepared by the method described in patent document WO 2011 / 090088.
[0465] Example 2: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satlizumab in Patients with Anti-N-Methyl-D-Aspartate Receptor (NMDAR) and Anti-Leucine-Rich Glioma Inactivated 1 (LGI1) Encephalitis
[0466] 1. introduction
[0467] 1.1. Research principles
[0468] The objectives of this study were to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satelizumab in participants with anti-N-methyl-D-aspartate receptor (NMDAR) and anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis.
[0469] Although NMDAR and LGI1 encephalitis are distinct, diagnostically distinguishable disease subtypes, both share core clinical features of seizures and cognitive impairment; therefore, it is appropriate to apply the same study endpoints, study duration, and study design to each subtype but to analyze the results of each subtype independently. To balance these considerations, participants with either of the two encephalitis types will be clearly divided into different cohorts, each with its own placebo control and analysis.
[0470] Current treatment for these diseases uses only off-label immunotherapies and is based on expert opinion, retrospective case series, and open-label studies. Several unmet needs exist, including the frequent occurrence of long-term cognitive deficits, inadequate seizure control, and frequent reliance on high-dose corticosteroids and faster-acting but durable immunotherapies. Evidence-based treatments need to be proposed prospectively to effectively mitigate the acute and long-term consequences of these diseases.
[0471] 1.2 Benefit-risk assessment
[0472] The aim of this study was to evaluate the efficacy and safety of the IL-6R blocker satelizumab to address the significant unmet medical needs of patients with AIE.
[0473] Although satelizumab has not been previously tested in patients with anti-NMDAR or anti-LGI1-mediated encephalitis, nonclinical and clinical data suggest that IL-6 plays a key role in the pathophysiology of these diseases. IL-6 is a proinflammatory cytokine with pleiotropic functions, including induction of differentiation and proliferation of proinflammatory Th17 cells and plasmablasts and plasma cell maturation. IL-6R blockade has the potential to modulate the immunopathogenic mechanisms of AIE, regardless of autoantibody type. Processes regulated by IL-6R signaling, such as B-cell and T-cell differentiation, B-cell proliferation, and regulation of the blood-brain barrier, are thought to play a role in the pathogenesis of anti-NMDAR (Armangue et al. 2018; Martinez-Hernandez et al. 2011; Bien et al. 2012; Leypoldt et al. 2015; Ding et al. 2018) and anti-LGI1-mediated AIE (Helmstaedter et al. 2021).
[0474] Nonclinical data generated using IL-6 knockout mice and IL-6 neutralizing antibodies demonstrated a clear role for IL-6 in the pathogenesis of experimental AIE. In rats administered NMDAR antibodies, brain infusion of IL-6 was associated with a worsening of NMDAR-mediated excitatory postsynaptic currents and was accompanied by exacerbated impairments in memory and learning (Wang et al., 2019). In addition, elevated cerebrospinal fluid IL-6 levels were observed in patients with NMDAR encephalitis and in patients with new-onset refractory status epilepticus, a condition often associated with AIE (Jun et al., 2018; Kirmani et al., 2018).
[0475] In addition, clinical case series suggest that IL-6R antagonists may be beneficial for patients with AIE and associated symptoms. A retrospective study demonstrated significant benefit from anti-IL-6R therapy (tocilizumab) in adult patients with different antibody subtypes (including anti-NMDAR and anti-LGI1) who had an incomplete response to previous rituximab therapy (Lee et al. 2016a; Lee et al. 2016b). Similar responses were found in children (Randell et al. 2018). The use of IL-6R antagonists in patients with new-onset NMDAR and CASPR2-positive AIE with recent onset of symptoms was also associated with significant clinical improvement (Lee et al. 2020; Krogias et al. 2013). Similar beneficial effects were observed in patients with “probable AIE” (i.e., meeting clinical criteria for AIE but without clear autoantibody association) (Lee et al. 2020). Finally, IL-6R inhibition has been associated with the termination of refractory status epilepticus, a life-threatening condition observed in up to 30% of AIE patients in acute care (Cadena et al., 2017; Jun et al., 2018).
[0476] Satlizumab has demonstrated efficacy and safety for the treatment of another autoantibody-mediated disease (ie, NMOSD) as monotherapy or as adjunct to immunosuppressive therapy (IST; ie, oral corticosteroids [OCS], azathioprine, or mycophenolate mofetil). A total of 178 participants were included in the double-blind phase of the Phase III study in NMOSD. Of the 178 participants, 104 participants received a 120 mg dose of satlizumab subcutaneously every 4 weeks (Q4W) and 74 participants received placebo. Overall, patients with NMOSD tolerated satlizumab well as monotherapy or in combination with IST.
[0477] All currently available AIE treatment options, including high-dose corticosteroids and cyclophosphamide, present substantial potential safety risks. There is no evidence from randomized controlled trials to support treatment decisions. Furthermore, not all patients respond to currently used medications, and drawbacks remain, including cognitive deficits, inadequate seizure relief, dependence on high-dose corticosteroids, and the need for longer-lasting, more rapid-acting medications. The proposed satelizumab trial will address these unmet needs and determine the effectiveness of satelizumab in patients with NMDAR or LGI1 encephalitis. Given the potential for efficacy in patients for whom no approved medications exist, the safety profile of satelizumab, and the risk mitigation measures studied, the benefit-risk ratio of satelizumab is expected to be acceptable for the treatment of both NMDAR and LGI1 encephalitis.
[0478] 2. Goals and End Points
[0479] This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satelizumab compared with placebo in the following cohorts:
[0480] *NMDAR AIE cohort: adults and adolescents with confirmed or probable NMDAR encephalitis
[0481] *LGI1 AIE cohort: adults with LGI1 encephalitis
[0482] For efficacy analyses, each cohort will be treated as a separate group with independent type I error control at the 5% significance level.
[0483] Table 1 lists the specific objectives and corresponding endpoints for the two cohorts in part 1 (main treatment period).
[0484] [Table 1]
[0485] Objectives and corresponding endpoints of Part 1
[0486]
[0487] ADA = antidrug antibodies; AIE = autoimmune encephalitis; BDI-II = Beck Depression Inventory, second edition; CASE = Clinical Assessment Scale for Autoimmune Encephalitis; C-SSRS = Columbia Suicide Severity Rating Scale; EEG = electroencephalogram; LGI1 = leucine-rich glioma inactivation 1; MFIS = modified fatigue impact scale; MOCA = Montreal global cognitive assessment; mRS = modified Rankin scale; NMDAR = N-methyl-D-aspartate receptor; PK = pharmacokinetics; QOL = quality of life; RAVLT = Rey Auditory Verbal Learning Test.
[0488] 3. Study Design
[0489] 3.1 Overall Design
[0490] 3.1.1 Overview of Study Design
[0491] This Phase III, randomized, double-blind, placebo-controlled, multicenter study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satelizumab compared with placebo in the treatment of NMDAR encephalitis and LGI1 encephalitis. For efficacy analyses, the NMDAR AIE and LGI1 AIE cohorts will be treated as separate groups in the basket study design. The study will include a screening period of up to 28 days during which patients will be assessed for eligibility to participate in the study. Screening will be followed by
[0492] *Part 1: 52-week main treatment period
[0493] *Part 2: Optional extension phase, starting from the last participant entering the extension phase or until commercial satelizumab becomes available for the treatment of AIE, lasting approximately 2 years
[0494] A pharmacokinetic (PK) interim analysis will be performed to confirm that target concentrations have been achieved (see Section 7.4.1).
[0495] During the global recruitment phase, all sites will enroll approximately 102 participants in the NMDAR AIE cohort and 50 participants in the LGI1 AIE cohort.
[0496] Figure 1 Provides research proposal.
[0497] 3.1.2 Part 1: Main treatment period
[0498] In part 1, participants will be randomized in a 1:1 ratio to receive placebo or 60 mg (<40 kg), 120 mg (between 40 and 100 kg), or 180 mg (>100 kg) of satelizumab in the NMDAR AIE and LGI1 AIE cohorts, respectively.
[0499] Randomization within each cohort will be stratified as follows:
[0500] * Patient population: Newly diagnosed patients and patients with incomplete response (as described in section 4.1.1)
[0501] *area
[0502] Blinded study medication will be administered subcutaneously to participants at Weeks 0, 2, 4, and subsequently Q4W until the end of Part 1, either as monotherapy or in addition to background treatment.
[0503] In Part 1, participants in both cohorts may receive background IST therapy (see Background Therapy, Section 5.1.2) and symptomatic treatment (see Symptomatic Treatment, Section 5.2.2) in addition to satelizumab or placebo, depending on the disease stage outlined in the inclusion criteria.
[0504] Participants who were receiving oral or intravenous corticosteroids at baseline and who were not in a critical care setting (ie, intensive care unit, high dependency unit) will have their OCS tapered using a standard taper beginning 4 weeks after randomization (week 4).
[0505] For participants who are in a critical care setting (ie, intensive care unit, high dependency unit) and are receiving oral or intravenous corticosteroids at baseline, steroid taper will be optional at the physician's discretion and, if performed, will follow the non-critical care setting taper schedule (as indicated above). After discharge from the intensive care unit, a non-critical care setting taper schedule will be instituted, provided that 4 weeks have elapsed since randomization (week 4 or later).
[0506] For safety reasons, the dose of background and symptomatic treatment may be reduced at any time.
[0507] The independent data monitoring committee (iDMC) will perform prespecified interim PK analyses and periodic safety reviews during Part 1. Interim PK analyses will be performed with the goal of confirming that achieved satelizumab exposure (and predicted receptor occupancy [RO]) is within the target range. Based on the results of the interim PK analyses and prespecified criteria, the dose of study drug may be increased (see Section 3.3 for satelizumab dosing rationale). The sponsor, participants, and investigators will remain blinded to the PK interim analyses, periodic safety reviews, and any optional efficacy interim analyses.
[0508] 3.2 Rationale for the study design
[0509] 3.2.1 Rationale for the study population and analysis groups
[0510] This study will investigate the treatment of patients with NMDAR and LGI1 encephalitis with satelizumab as separate cohorts in a single trial, each containing its own placebo group and analyzed separately with independent type I error control at the 5% significance level. The population for this study will include participants who meet clinical criteria for diagnosis of NMDAR or LGI1 encephalitis (see Section 4.1; adapted from Graus et al. 2016) and whose AIE has resulted in a decline in function and ability to perform previously performed activities (defined as an mRS score <2).
[0511] The identification of antibodies against neuronal cell surface and synaptic proteins that are thought to be directly pathogenic has described a population that generally responds better to immunotherapy. Of these, anti-NMDAR and anti-LGI1-mediated encephalitis are the most common (Leypoldt et al., 2013) and best characterized syndromes.
[0512] NMDAR encephalitis is associated with CSF IgG antibodies against the NMDAR GluN1 subunit. These antibodies are highly specific and their pathogenicity has been demonstrated in cultured neurons and in vivo models. In clinical practice, antibody studies should include CSF analysis; if only serum is used, there is a risk of false-negative or false-positive diagnosis (Graus et al., 2016).
[0513] In clinical practice, obtaining anti-NMDAR testing (particularly CSF sampling for anti-NMDAR antibodies) may be inconsistent, delayed, or difficult to achieve. Treatment decisions are often made based on clinical features. Therefore, criteria for possible NMDAR encephalitis were published in a consensus document and have shown high sensitivity and specificity in adults (87.2% and 96.7%, respectively; Kaneko 2018), Australian children (90% and 96%, respectively; Ho et al. 2017), and Japanese children (81.2% and 76.9%, respectively; Nishida et al. 2021).
[0514] All participants in this study will receive first-line treatment (e.g., high-dose corticosteroids, IVIG, or plasma exchange) prior to randomization, and participants in the “incomplete responder” category will receive immunotherapy more than 6 weeks after acute first-line therapy. The administration of these therapies may affect anti-NMDAR antibody testing, resulting in false positives and false negatives (Gruter et al., 2020). Therefore, confirmation of antibody positivity in a population already receiving treatment may not be a reliable diagnostic gold standard, and requiring antibody positivity before treatment will limit applicability and recruitment.
[0515] Given that many patients with possible NMDAR encephalitis are managed on the basis of highly suggestive clinical features in clinical practice and given the demonstrated utility of the “possible” criterion and the possible impact of immunomodulatory therapy on anti-NMDAR antibody testing, the study population will include both definite NMDAR encephalitis (defined by consensus criteria requiring CSF antibody positivity and consistent clinical features) and possible NMDAR encephalitis (defined by consensus criteria requiring strict clinical features combined with positive ancillary clinical examinations [CSF and EEG]) in the NMDAR population.
[0516] Despite concerns about interference with testing due to prior medication, serum collection is likely to become more widely used worldwide given that it is more sensitive than CSF for diagnosing LGI1 encephalitis (van Sonderen et al. 2016). Although consensus diagnostic criteria have not yet been published, diagnostic criteria requiring key clinical features for use in conjunction with a positive serum or CSF sample have been developed and outlined in protocols, described in a consensus document (Graus et al. 2016) for limbic encephalitis (a common clinical presentation), and confirmed in the largest published series of LGI1 AIE (van Sonderen et al. 2016).
[0517] Because the significance and pathogenicity of antibodies to intracellular antigens are unknown and their association with cancer is high, patients with a diagnosis or history of these antibodies will be excluded from the study. Specifically, patients with a known diagnosis or history of anti-Hu, anti-Ma2, anti-CRMP5, anti-Yo, anti-ampalin, AMPA, mGluR5, and GABA B Patients with a history of positive antibody testing will be excluded. Similarly, patients with untreated teratoma / thymoma, a history of malignancy (unless considered cured with adequate treatment and with no evidence of recurrence within 5 years prior to screening), or a confirmed case of paraneoplastic encephalitis will be excluded.
[0518] 3.2.2 Rationale for control groups
[0519] The control group in the study will receive a placebo. Participants may continue to receive their elective background therapy at a stable dose in Part 1, as described in Section 5.1.2. The use of placebo in this setting will help determine the efficacy and safety of satelizumab in a clinical setting that represents the real-world situation in patients with AIE. Placebo-controlled data for the NMDAR and LGI1 encephalitis subtypes will not only provide evidence for these individual syndromes, for which there are no approved drug treatments, but may also generate information relevant to the understanding of AIE more broadly.
[0520] 3.2.3 Rationale for the Pharmacokinetic Sample Collection Schedule
[0521] To explore the pharmacokinetics of satelizumab in the NMDAR / LGI1 encephalitis population after long-term treatment, samples will be collected to assess serum concentrations of satelizumab before each administration of study drug. These assessments will include analysis of the effects of a range of covariates on exposure (e.g., sex, race, age, and weight), as well as analysis of the relationship between exposure and PD, efficacy, immunogenicity, and safety endpoints to support the recommended dose of satelizumab in the NMDAR / LGI1 encephalitis population. PK assessments will also be used to guide PK interim analyses to confirm the appropriate dose of satelizumab in the AIE population.
[0522] 3.2.4 Rationale for immunogenicity sample collection
[0523] Serum samples for ADA will be collected in parallel with PK samples to assess the incidence and titer-time profile of ADA in the NMDAR / LGI1-encephalitis population and the impact on satelizumab exposure, as well as the impact on safety and efficacy. In addition to subsequent analyses based on the full study dataset, ADA data will be included in the blinded review of PK data at Week 8 to aid in the interpretation of satelizumab concentration data.
[0524] 3.2.5 Rationale for biomarker assessment
[0525] This study will evaluate whether biomarkers can help characterize the mechanism of action of satelizumab in NMDAR / LGI1 encephalitis, provide evidence of satelizumab activity in NMDAR / LGI1 encephalitis, or increase knowledge and understanding of the disease biology of NMDAR / LGI1 encephalitis.
[0526] 3.2.6 Rationale for the selection of the primary endpoint
[0527] The inventors propose to use the modified Rankin Scale (mRS) as the primary outcome measure for this Phase III trial to assess the benefit of satelizumab on multiple symptoms affecting the clinical status and disability of participants with NMDAR or LGI1 encephalitis. The mRS is a score that measures the degree of disability and dependence.
[0528] The reasons for choosing the mRS scale are as follows:
[0529] *Proven Validity and Reliability: The mRS was developed by Dr. John Rankin to assess stroke severity (7 severity levels: 0 = no symptoms at all to 6 = death) and functional limitations in performing activities of daily living (i.e., ability to walk and ability to perform daily duties and activities), which have been shown to be present and clinically meaningful in patients with AIE. The mRS demonstrated good construct validity when correlated with the Clinical Assessment Scale for AIE (CASE), a recently developed scale for AIE that measures symptom severity (r = 0.86, p = 0.001; Lim et al., 2019). Test-retest reliability was established in a sample of patients (n = 48) questioned at two independent assessments and showed a high degree of reproducibility (r = 0.94; Wilson et al., 2005).
[0530] *Content validity in NMDAR encephalitis: The complex neuropsychiatric manifestations and global cognitive impairment of NMDAR encephalitis lead to patient disability and dependence, which is well reflected in the mRS score. In addition, the score is simple and straightforward to administer and understand for clinicians in the acute neurology setting. The mRS has also been used in patients with NMDAR encephalitis to study short-term and long-term outcomes of commonly used medications (Titulaer et al. 2013; Gadoth et al. 2017). Therefore, the inventors believe that the mRS scale will adequately measure clinically significant neurological improvements in patients with NMDAR encephalitis while representing the most clinically meaningful outcomes for a group of patients with disabling and often diverse symptoms (Dubey et al., 2015).
[0531] *Content validity in LGI1 encephalitis: Impairments in LGI1 encephalitis manifest primarily as anatomically restricted cognitive impairments affecting memory and seizures, but also include behavioral impairments with major impacts on ability and dependency, which can be assessed and measured simply using the mRS score. Furthermore, studies have shown that changes in mRS scores in patients with positive LGI1 AIE generally coincide with changes in key symptoms such as seizure frequency and cognitive deficits (van Sonderen et al., 2016), suggesting that this scale is a reasonable measure of how the major individual symptoms associated with LGI1 encephalitis affect patients' daily functioning. For these reasons, the mRS has been used to study short- and long-term outcomes in patients with LGI1 AIE in the existing literature examining the natural history of treatment (van Sonderen et al. 2016; Gadoth et al. 2017; Gadoth et al. 2018).
[0532] *Guidance on the assessment scale will be tailored to important aspects of assessing AIE during the patient interview, including cognitive deficits (memory loss). To ensure consistency, this guidance will be part of mandatory mRS training for all sites.
[0533] Finally, the mRS has also been used as a primary endpoint in several randomized, controlled, and open-label studies of AIE that have included patients with both NMDAR and LGI encephalitis (NCT04372615, NCT03993262, NCT03542279, and NCT04175522). Existing data on the mRS scale in AIE have been used to help guide proposed study designs, particularly regarding expected changes in the placebo group (Gadoth et al. 2017; Titulaer et al. 2013).
[0534] The primary endpoint for the NMDAR AIE and LGI1 AIE cohorts will assess the difference in the proportion of responders between satelizumab and placebo at Week 24 in patients with NMDAR encephalitis and LGI1 encephalitis, respectively.
[0535] Responders were defined as participants who had an improvement of 1 or more mRS score from baseline at week 24 and who did not use rescue therapy. Based on the range of severity covered by the scale grades (Banks and Marotta 2007; Harrison et al. 2013), a change of one mRS grade is considered clinically meaningful and is used in AIE clinical practice and observational studies to represent a meaningful change in a patient's ability to participate in activities of daily living. The inventors recommend that patients who were at least unable to perform all previous activities (measured by an mRS of 2 or higher) at baseline be included. Therefore, an improvement of 1 (rather than an mRS score of 0-2, which generally corresponds to a "good outcome" on the scale) will be sufficient to capture meaningful improvements in all participants in the study with varying levels of symptom levels and degrees of disability. Additional data will be collected as part of secondary and exploratory endpoints using the mRS scale (mRS score [measured on a 7-point scale] and proportion of participants with an mRS score of 2 or lower).
[0536] 3.3 Rationality of Dosage and Schedule
[0537] As shown in Table 2 , weight-stratified dosing with SC injection will be used in this study to investigate the efficacy and safety of satelizumab in NMDAR and LGI1 encephalitis.
[0538] [Table 2]
[0539] Investigational dosing regimen in a phase III study of satelizumab for NMDAR and LGI1 encephalitis
[0540] Baseline weight Dosage and regimen <40kg 60 mg subcutaneously at Weeks 0, 2, 4, and Q4W thereafter ≥40-100kg 120 mg subcutaneously at Weeks 0, 2, 4, and then Q4W >100kg 180 mg subcutaneously at Weeks 0, 2, 4, and then Q4W
[0541] PK = pharmacokinetics; Q4W = every 4 weeks.
[0542] NOTE: Dose may be increased following interim PK analysis as detailed below.
[0543] The dosing regimen was based on a combination of information sources, including PK, PD, and safety data for satelizumab used in initial development for NMOSD.
[0544] A fixed dosing regimen of 120 mg (administered at weeks 0, 2, and 4, then Q4W) studied in a phase III study in NMOSD was associated with high predicted trough receptor occupancy (RO) at steady state in most participants. tr,ss ) (median 95% or higher) and was shown to be safe and effective in all weight groups (i.e., 40 kg and above). The 4-week maintenance dosing interval is supported by the approximately 30-day half-life of satelizumab. tr,ssThe few NMOSD participants with values <80% generally had a baseline weight greater than 100 kg, and although the safety profile was similar across weight groups, participants with the lowest weight had satelizumab exposures exceeding those required to maintain near-maximal RO tr,ss Required exposure.
[0545] Given the expected similarity in target expression between NMOSD and NMDAR / LGI1 encephalitis patients, it was expected that exposures similar to those seen in NMOSD would also be effective for NMDAR and LGI1 encephalitis. Therefore, the inventors performed simulations using an existing popPK model (based on data from healthy volunteers and NMOSD participants) to estimate the potential to achieve the same near-maximal RO for NMDAR and LGI1 encephalitis participants across the expected weight range. tr,ss value the required dose to maximize the potential for therapeutic efficacy.
[0546] These simulations indicate that the proposed weight-based dosing regimen is expected to achieve median maximum concentrations observed at steady state (C max )(C max,ss ) value and steady-state trough concentration (C tr,ss ) values, which correlated with near-maximal RO throughout the dosing interval (see Figure 2 The predicted exposure range for participants weighing >100 kg receiving 180 mg of satelizumab does not significantly exceed the maximum exposure achieved in the NMOSD Phase III trial and is therefore within the existing exposure safety range. Conversely, the predicted exposure of the 60 mg regimen in participants <40 kg is expected to be sufficient to maintain high target engagement over the dosing interval and avoid unnecessary overexposure.
[0547] The initial dose set for this Phase III study was based on the assumption that the pharmacokinetics of satelizumab in participants with NMDAR and LGI1 encephalitis would be similar to that in NMOSD. However, the inventors noted that there may be PK differences between the different populations, such as higher clearance (CL) values in healthy volunteers than in the NMOSD population (covariate value: 95.8%; 95% CI: 67.5 to 124.1). Therefore, the proposed study design provided for a PK interim analysis to confirm the initial dose or, if the CL in the NMDAR / LGI1 population was higher (as observed in healthy volunteers), to increase the dose to a pre-specified level based on the recommendations of the iDMC, while the sponsor remained blinded to help maintain the integrity of this pivotal study. See Section 7.4.1 for more details on the proposed PK interim analysis.
[0548] In cases where the initially proposed dose did not achieve the target exposure, simulations using the existing popPK model have been used to define alternative doses. Given that the targets are the same (i.e., for NMOSD and NMDAR / LGI1 encephalitis) and the target expression is expected to be similar for NMDAR and LGI1 encephalitis, it was considered appropriate to use the existing RO model as the basis for predicting RO in this interim analysis. If the CL values in this study reflect the CL values of healthy volunteers (higher than the CL values of the NMOSD population), the dose adjustment options would be to increase the dose of participants to the predefined dosing regimens of 120 mg (<40 kg), 180 mg (between 40 and 100 kg), and 240 mg (>100 kg). In either case, the selected dosing regimen will be associated with an exposure that does not significantly exceed the existing exposure safety range.
[0549] PK parameters in adolescent participants with NMOSD were similar to those in adult participants, and the dosing regimen resulted in projected exposures that were supported by the existing safety profile established in Phase III studies in adult and adolescent NMOSD participants.
[0550] 3.4 Definition of study end
[0551] A participant can be considered to have completed the study if he or she has completed all phases of the study (including the last visit / last scheduled procedure).
[0552] The end date of this study was defined as the last visit date of the last participant in the study for either cohort or the date on which the last data point required for statistical analysis or SFU was received from the last participant in either cohort (whichever was later).
[0553] 4. Part 1 is expected to end 52 weeks after the last participant is enrolled in the study cohort
[0554] Participants with NMDAR encephalitis and participants with LGI1 encephalitis will be recruited during the global recruitment phase of this study.
[0555] Protocol deviations from prior approval of recruitment and enrollment criteria, also known as protocol waivers or exemptions, are not permitted.
[0556] 4.1 Inclusion criteria
[0557] Participants in the NMDAR AIE cohort must meet the inclusion criteria outlined in Sections 4.1.1 and 4.1.2. Participants in the LGI1AIE cohort must meet the inclusion criteria outlined in Sections 4.1.1 and 4.1.3.
[0558] 4.1.1 Inclusion criteria for all participants
[0559] Only participants who met the following criteria were eligible for inclusion in the study:
[0560] * Ability to sign informed consent, including compliance with the requirements and restrictions outlined in the informed consent form and this draft
[0561] *Tumor or malignancy should be reasonably excluded before baseline visit (randomization)
[0562] * AIE symptoms occurred within 9 months before randomization
[0563] *Meets the definition of “new onset” or “incomplete responder” AIE
[0564] Participants will be subdivided into “new onset” or “incomplete responders” based on the interval between initial first-line therapy and the start of study treatment and any additional therapy received, as follows:
[0565] - New onset: defined as participants with NMDAR or LGI1 AIE who meet the following criteria:
[0566] o A stable mRS score (at least 24 hours) of 2 or higher at baseline
[0567] o Received first acute first-line therapy within 6 weeks prior to randomization (baseline visit)
[0568] Acute first-line therapy was defined as at least 3 days of intravenous methylprednisolone at a dose of 500 mg or more per day (or equivalent oral corticosteroid dose) and / or at least 3 days of IVIG therapy and / or PLEX, or any combination of these. OCS and / or repeated courses of acute first-line therapy (after the initial course) were permitted. For LGI AIE participants receiving OCS, they were required to be taking 20 mg or more of prednisolone (or its equivalent) per day at the time of randomization. After randomization, the tapering schedule in Section 3.1.2 should be followed.
[0569] o Not received rituximab or any other IST (e.g., cyclophosphamide, mycophenolate mofetil, methotrexate, cyclosporine, tacrolimus, azathioprine) or tocilizumab for AIE
[0570] - Incomplete responders: defined as participants with NMDAR or LGI1 AIE who meet the following criteria:
[0571] o A stable mRS score (at least 24 hours) of 2 or higher at baseline
[0572] o Received first acute first-line therapy more than 6 weeks prior to randomization (baseline visit). Acute first-line therapy was defined as at least 3 days of intravenous methylprednisolone at a dose of 500 mg or more per day (or equivalent oral glucocorticoid dose) and / or at least 3 days of IVIG therapy and / or PLEX, or any combination of these.
[0573] Received immunotherapy in addition to the first course of acute first-line therapy. The following conditions must be met:
[0574] *For participants who have received rituximab, the treatment course started at least 2 months before screening, the last dose was administered at least 4 weeks before randomization, and there was no improvement in mRS score within 4 weeks before randomization
[0575] *For participants receiving other IST (i.e., mycophenolate mofetil, cyclophosphamide [IV only], or azathioprine), at least 2 months of treatment prior to screening, dose was stable for at least 4 weeks prior to screening, and no improvement in mRS score within 4 weeks prior to randomization
[0576] *For participants receiving OCS, stable daily prednisolone 20 mg or more (or its equivalent) with no increase in steroid dose within 4 weeks prior to screening and no improvement in mRS score within 4 weeks prior to randomization
[0577] *For participants who have received repeated courses (pulse) of acute first-line therapy, treatment must have been completed at least 2 weeks prior to randomization (baseline visit)
[0578] 4.1.2 Additional inclusion criteria for the NMDAR AIE cohort
[0579] In addition to the criteria outlined in Section 4.1.1, participants were eligible for inclusion in the NMDARAIE cohort if they met the following criteria:
[0580] * Age 12 years or older when signing the informed consent form
[0581] For adolescent participants or participants who are unable to give consent due to the severity of their illness, a legally authorized representative can sign the informed consent form and obtain the participant's assent according to local requirements.
[0582] *Signed consent where appropriate based on patient age and individual site and country standards
[0583] * Possible or confirmed diagnosis of NMDAR encephalitis is as follows:
[0584] Probable NMDAR encephalitis is diagnosed when the following three criteria are met:
[0585] 1. Rapid onset (less than 3 months) of at least four of the following six major symptoms:
[0586] - Abnormal (psychiatric) behavior or cognitive dysfunction
[0587] - Speech disorders (speech stress, hypospeech, mutism)
[0588] - Seizures
[0589] - Movement disorders, ataxia, or rigidity / abnormal posture
[0590] -Decreased level of consciousness
[0591] -Autonomic dysfunction or central hypoventilation
[0592] 2. At least one of the following laboratory test results:
[0593] -EEG abnormalities (focal or diffuse slow or disorganized activity, epileptic activity, or extreme delta brush)
[0594] - Pleocytosis or oligoclonal bands in CSF
[0595] 3. Reasonably exclude other causes and other clear encephalitis syndromes (e.g., Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, Hashimoto encephalopathy, primary vasculitis of the central nervous system (CNS), and Rasmussen encephalitis).
[0596] If accompanied by systemic teratoma, possible NMDAR encephalitis can also be diagnosed in the presence of the above three groups of symptoms in criterion 1.
[0597] Definite NMDAR encephalitis is diagnosed when three of the following criteria are met:
[0598] 1. The presence of one or more of the six cardinal symptoms described in Criteria 1 for possible NMDAR encephalitis,
[0599] 2. Documented history or detection of anti-NMDAR (GluN1) IgG antibodies in cerebrospinal fluid using cell-based testing at screening
[0600] 3. Reasonably exclude other causes and other clear encephalitis syndromes (e.g., Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, Hashimoto's encephalopathy, primary CNS vasculitis, and Rasmussen's encephalitis).
[0601] 4.1.3 Additional inclusion criteria for the LGI1 AIE cohort
[0602] In addition to the criteria outlined in Section 4.1.1, participants were eligible for inclusion in the LGI1AIE cohort if they met the following criteria:
[0603] *Age 18 or above when signing the informed consent form
[0604] For participants who are unable to give consent due to the severity of their illness, a legally authorized representative may sign an informed consent form and obtain the participant's assent according to local requirements.
[0605] *LGI1 encephalitis diagnosis
[0606] LGI1 encephalitis can be diagnosed if the following criteria are met:
[0607] 1. Documented medical history or detection of anti-LGI1 IgG antibodies (in serum or cerebrospinal fluid) using a cell-based assay at screening
[0608] 2. Subacute onset (less than 4 months of progression) of working memory impairment, seizures (including faciobrachial dystonic seizures), or psychiatric symptoms suggestive of limbic system involvement
[0609] The diagnosis of LGI1 encephalitis should be based on reasonable exclusion of other etiologies and other well-defined encephalitis syndromes (eg, Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, Hashimoto encephalopathy, primary CNS vasculitis, and Rasmussen encephalitis).
[0610] 4.2 Exclusion criteria
[0611] Participants were excluded from the study if they met any of the following criteria:
[0612] *Any untreated teratoma or thymoma at baseline visit (randomization)
[0613] A teratoma or thymoma detected before or during screening was allowed if considered cured after treatment (usually surgical resection) 1 week before baseline
[0614] * History of cancer or malignancy, unless fully treated and cured, with no signs of recurrence for at least 5 years prior to screening (except for basal cell carcinoma and squamous cell carcinoma of the skin, or carcinoma in situ of the cervix that has been completely removed and cured)
[0615] *For patients with NMDAR AIE, history of negative anti-NMDAR antibodies in cerebrospinal fluid using a cell-based assay within 9 months of symptom onset
[0616] * Patient history is known to be positive for intracellular antigens that are highly associated with cancer (e.g., anti-Hu, anti-Ma2, anti-CRMP5, anti-Yo, anti-amphoprotein, AMPA, mGluR5, and GABAB ) or GAD-65
[0617] * Patient history is known to be positive for any cell surface neuronal antibodies other than NMDAR and LGI1 (e.g., caspr2, IgLON5, DPPX, GABA A and neuronal surface protein-3α)
[0618] * Confirmed paraneoplastic encephalitis
[0619] * A confirmed demyelinating disease of the central or peripheral nervous system (eg, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy)
[0620] *Other causes of associated symptoms, including central nervous system infection, septic encephalopathy, metabolic encephalopathy, epilepsy, mitochondrial disease, Kleine-Levin syndrome, Creutzfeldt-Jakob disease, rheumatic disease, Reyes syndrome, or inherited metabolic defects
[0621] * History of herpes simplex encephalitis within the past 24 weeks
[0622] 5. Study treatment and concomitant therapy
[0623] Study treatment is defined as any investigational treatment, marketed product, placebo, or medical device intended to be administered to study participants according to the study protocol.
[0624] The investigational drugs (IMPs) for this study were satelizumab and placebo. Background therapy, rescue therapy, and symptomatic treatment were considered non-IMPs.
[0625] 5.1 Study Treatment Administered
[0626] 5.1.1 Satlizumab versus placebo
[0627] The test product for this study is satelizumab. In this protocol, "study drug" means satelizumab or placebo (specified on the basis of background therapy). In Part 1, study drug will be administered at site visits at Weeks 0, 2, 4, and subsequently Q4W. Participants will receive 60 mg (less than 40 kg), 120 mg (40 to 100 kg), or 180 mg (greater than 100 kg) of satelizumab, depending on body weight.
[0628] Study medication will be administered by SC injection in the abdominal or femoral area after all other study-related procedures have been performed at the site visit.
[0629] 5.1.2 Background treatment
[0630] Participants classified as “incomplete responders” (see Section 4.1.1) may have received or will continue to receive background therapy in addition to study drug during Part 1.
[0631] Examples of background therapeutic drugs include:
[0632] * Azathioprine
[0633] *Mycophenolate mofetil
[0634] *IV cyclophosphamide
[0635] Please refer to Section 5.2.2 for symptomatic medications permitted during the study.
[0636] For participants who discontinued background therapy prior to study entry, study eligibility (see section 4.2) must be met with complete blood count and differential blood count at the time of randomization.
[0637] 5.2 Concomitant therapy
[0638] Concomitant therapy consists of any medications (e.g., prescription medications, over-the-counter medications, vaccines, herbal or homeopathic medications, and / or nutritional supplements) used by the participant in addition to protocol-mandated therapy between 7 days prior to starting study treatment and the last SFU visit. All such medications must be recorded on the Concomitant Medication eCRF with the following information:
[0639] *Reason for use
[0640] *Date of application, including start and end dates
[0641] * Dosage information, including dose and frequency
[0642] If you have any questions regarding concomitant or previous therapy, consult your medical supervisor.
[0643] The use of paracetamol / acetaminophen at a daily dose of 2 g or less was permitted at any time during the study and screening periods.
[0644] 5.2.1 Rescue therapy
[0645] Rescue therapy was defined as initiation or dose increase of IST medication (see section 5.1.2 for details on permitted background therapy), rituximab, OCS, re-administration of first-line immunotherapy (IVIG, IV methylprednisolone, or plasma exchange), or failure to taper OCS as directed by the protocol.
[0646] The following rescue procedures may be used:
[0647] * Plasma exchange (PLEX)
[0648] The following rescue medications may be used:
[0649] *IVIG
[0650] *Rituximab
[0651] *IV cyclophosphamide
[0652] * Azathioprine
[0653] *Mycophenolate mofetil
[0654] *Corticosteroids (OCS or IV methylprednisolone)
[0655] 5.2.2 Symptomatic treatment
[0656] The following drugs commonly used for the symptomatic treatment of AIE (Abboud et al., 2021) were allowed and are described below:
[0657] *AEDs (eg, carbamazepine, lacosamide, levetiracetam)
[0658] *Analgesics (eg, topical medications, anticonvulsants [eg, pregabalin, gabapentin, carbamazepine])
[0659] * Antidepressants (eg, tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors [eg, duloxetine])
[0660] *Antipsychotics (eg, quetiapine)
[0661] *Mood stabilizers (such as valproic acid)
[0662] * Beta-blockers (eg, propranolol)
[0663] * Alpha-2 blockers (eg, clonidine)
[0664] * alpha-adrenergic agonists (eg, midodrine)
[0665] *Acetylcholinesterase inhibitors (eg, pyridostigmine) are used to increase sympathetic drive
[0666] * Non-opioid analgesics (eg, paracetamol or acetaminophen, nonsteroidal anti-inflammatory drugs)
[0667] *Modafinil or melatonin for sleep disorders
[0668] * Antimuscarinics, muscle relaxants, antidopaminergic drugs, and dopamine agonists for movement disorders
[0669] 5.2.3 Other permitted treatments
[0670] In general, investigators may manage the care of participants (including pre-existing conditions) through the use of supportive therapies as clinically indicated and consistent with local standard practice, except for contraindicated therapies, and with consideration of prudent therapies. Participants who experience infusion-related symptoms may use paracetamol / acetaminophen, ibuprofen, diphenhydramine, and / or H 2 Symptomatic treatment with receptor antagonists (e.g., famotidine, cimetidine) or equivalent drugs. Severe infusion-related events manifested as dyspnea, hypotension, wheezing, bronchospasm, tachycardia, decreased oxygen saturation, or respiratory distress should be treated with supportive therapy (e.g., supplemental oxygen and beta-2-adrenergic agonists) as clinically indicated.
[0671] Preemptive use of antihistamines, antipyretics, and / or analgesics was allowed at the investigator's discretion.
[0672] The following concomitant therapies were permitted, as described below:
[0673] *Oral contraceptives (see section 4.1)
[0674] * Hormone replacement therapy
[0675] *Background treatments listed in Section 5.1.2.
[0676] * Use topical (e.g., ophthalmic, nasal, otologic, dermatologic) corticosteroids to treat adverse events (i.e., indications beyond background AIE therapy), but treatment duration should be as short as possible
[0677] * Non-pharmacological interventions (e.g., individual psychotherapy, cognitive behavioral therapy, physical therapy, and rehabilitation)
[0678] 6. Research Assessment and Procedures
[0679] 6.1 Efficacy evaluation
[0680] Participants will undergo efficacy assessments at screening and at subsequent time points. Assessments to assess efficacy will include participant-reported (PRO), performance-based (PerfO), and clinician-reported outcomes (ClinRO) (see section 6.2); as well as any optional assessments that capture disease severity (including lumbar puncture). In addition, EEG will also be analyzed as an exploratory outcome (see section 6.3).
[0681] 6.2 Clinical outcome assessment
[0682] Performance-based outcomes (PerfO) and clinician-reported outcomes (ClinRO) tools will be completed to assess the treatment benefit of satelizumab.
[0683] The clinical outcome assessment tools are listed in Table 3 .
[0684] [Table 3]
[0685] Clinical outcome assessment
[0686]
[0687]
[0688] CASE = Clinical Encephalitis Assessment Scale; ClinRO = clinician-reported outcome, C-SSRS = Columbia-Suicide Severity Rating Scale; MOCA = Montreal Cognitive Assessment; mRS = modified Rankin Scale; PerfO = performance-based outcome; RAVLT = Rey Auditory-Verbal Learning Test.
[0689] 6.2.1 Data Collection Methods for Clinical Outcome Assessment
[0690] In the clinic, tools will be used before participants receive any information about disease status, before non-PRO (participant reported outcome) assessments are performed, and before study treatment is administered, unless otherwise specified.
[0691] The PerfO and ClinRO tools will be completed in the clinic at designated time points during the study. The PerfO and ClinRO tools will be administered prior to completion of the physical examination, prior to any safety assessments, and prior to study treatment. Clinicians must complete the official version of each ClinRO tool as provided by the Sponsor. Scales may not be copied from the protocol.
[0692] 6.2.2 Description of the Clinical Outcome Assessment Tool
[0693] 6.2.2.1 Modified Rankin Scale (mRS)
[0694] The mRS is a scale developed to measure the overall degree of disability after stroke and has been widely used to assess primary outcomes in randomized controlled trials of acute stroke management (Rankin 1957). The 7-point scale focuses on motor function and assesses walking ability to measure functional independence. The mRS is a clinician-rated assessment that contains six levels from 0 to 5, where 0 represents no symptoms and 5 represents severe disability. Higher scores indicate more severe disability. A separate category (out of 6) is often added to classify patients who die before the assessment window. An example of this scale is given by Banks JL et al. (Stroke. 2007; 38: 1091-1096). In the absence of a validated disease-specific scale, the mRS is often used to measure neurological outcomes of AIE. The mRS and its associated structured interview take approximately 15 minutes to complete and will be conducted at designated time points.
[0695] 6.2.2.2 Clinical Encephalitis Assessment Scale (CASE)
[0696] CASE is a new scale for assessing the severity of various AIE syndromes in patients and contains nine items (seizures, memory dysfunction, psychiatric symptoms, consciousness, language problems, movement disorders / dystonia, gait instability and ataxia, brainstem dysfunction, and weakness). The maximum score for each item is 3 points, and the higher the score, the greater the severity of the symptoms. The total score ranges from 0 to 27. CASE has been developed for clinical practice and may help overcome the limitations of current AIE outcome scales in future clinical trials (Lim et al., 2019). Lim JA et al. presented an example of the scale (Ann Neurol. 2019 Mar; 85 (3): 352-358.). CASE takes approximately 10 minutes to complete and will be administered at designated time points.
[0697] 6.2.2.3 Montreal Cognitive Assessment (MOCA)
[0698] The MOCA is a 30-item measure of global cognitive function designed to detect early suspected cognitive deficits. It covers the following cognitive domains:
[0699] * Sense of direction: know the day, date and your current location
[0700] * Short-term memory recall: the ability to hear a word and repeat it a short time later
[0701] * Concentration and spatial awareness: connect the numbered dots in sequence and draw three-dimensional shapes
[0702] * Language: The ability to speak and understand whole sentences and remember the names of familiar animals or objects
[0703] * Concentration: Repeat simple sequences in forward and reverse directions
[0704] * Visual-spatial: Perform a clock drawing test (i.e. used to assess dementia warning signs)
[0705] The MOCA takes only a few minutes to complete and is available in three versions to reduce the learning impact that may occur if it is administered every 3 months or less frequently. MOCA scores range from 0 to 30. Higher scores indicate better cognitive function. Scores of 26 or above are considered normal cognitive function (see https: / / www.mocatest.org / ). The MOCA will be administered at designated time points.
[0706] 6.2.2.4Rey Auditory Verbal Learning Test (RAVLT).
[0707] The RAVLT is a neuropsychological test that uses language to assess immediate memory span, new learning, sensitivity to interference, and recognition memory. The number of words recalled per trial is a measure of performance.
[0708] After five free recall trials, a second “interference” list (List B) is presented in the same manner, and participants are asked to recall as many words from List B as possible. Immediately after the distractor trial, participants are asked to recall the words from List A that they had heard five times previously. After a 30-minute delay, participants are asked to recall the words from List A again. After this “delayed recall” task, a list of 50 words is presented that contains all the words from Lists A and B, plus 20 words that are phonemically and / or semantically similar. This trial directly tests recognition memory rather than free recall. The multiple memory processes assessed by the RAVLT provide rich data about memory ability (Peaker and Stewart 1989; Spreen and Strauss 1991). The higher the score, the better the memory ability. The RAVLT takes approximately 35 minutes to complete and will be administered at designated time points.
[0709] 6.2.2.5 Columbia-Suicide Severity Rating Scale (C-SSRS)
[0710] The C-SSRS is a clinician-rated tool used to assess suicidality throughout a patient's lifetime and to track suicidal events throughout treatment. The scale will be administered at designated time points to allow timely recapture of suicidal ideation, including intensity of suicidal ideation, behaviors, and attempts of actual and potentially lethal nature. A "C-SSRS at Baseline" will be collected at baseline and a "C-SSRS since last visit" will be collected at follow-up visits. The C-SSRS takes 5-10 minutes to complete. Sample C-SSRS forms are available online at https: / / cssrs.columbia.edu / .
[0711] 6.2.2.6 Seizure diary
[0712] A seizure diary will be provided for the participant or caregiver to fill out. Instructions will be provided on how to collect seizure type, frequency, and duration.
[0713] 6.3 Additional Exploratory Evaluation
[0714] 6.3.1 Electroencephalogram
[0715] Participants will undergo EEG at designated time points.
[0716] Details of EEG assessment and data processing will be described in a separate EEG recording and processing manual.
[0717] 7. Statistical considerations
[0718] This study will compare the efficacy of satelizumab to matching placebo, administered for 52 weeks, in patients with NMDAR and LGI1 encephalitis as defined by the study eligibility criteria. The NMDAR AIE and LGI1 AIE cohorts will be considered separate populations and analyzed separately. Each cohort will have independent type I error control at the 5% significance level. Unless explicitly stated otherwise, statistical considerations are the same for the NMDAR AIE and LGI1 AIE cohorts. Participants receiving background therapy will need to follow the protocol-defined rules of Part 1, as described in Section 5.1.2.
[0719] 7.1 Statistical Assumptions
[0720] This study is designed to demonstrate the superiority of satelizumab over placebo. The primary and secondary efficacy analyses will compare satelizumab to placebo in the following groups:
[0721] *NMDAR AIE cohort: adults and adolescents with confirmed or probable NMDAR encephalitis
[0722] *LGI1 AIE cohort: adults with LGI1 encephalitis
[0723] The primary efficacy analysis will compare satelizumab with placebo at week 24. The following null and alternative hypotheses will be tested at a 5% two-sided significance level in each NMDAR and LGI1 AIE cohort:
[0724] H 0 :p 萨特利珠单抗 =p 安慰剂 VSH 1 :p 萨特利珠单抗 ≠p 安慰剂 ,
[0725] where p 萨特利珠单抗 and p 安慰剂 The proportions of participants in the satelizumab group and the placebo group who achieved an improvement of at least 1 point from baseline in the mRS at week 24 and did not use rescue therapy, respectively.
[0726] A similar format of null and alternative hypothesis testing will be performed for all secondary efficacy analyses. Note that all hypothesis tests are two-sided unless otherwise stated.
[0727] 7.2 Sample size determination
[0728] In the NMDAR AIE cohort, approximately 102 participants with NMDAR encephalitis will be randomized to study treatment so that approximately 92 evaluable participants will complete the study for this cohort. In the LGI1 AIE cohort, approximately 50 participants with LGI1 encephalitis will be randomized to study treatment so that approximately 45 evaluable participants will complete the study for this cohort.
[0729] For each cohort, participants will be randomly assigned to each treatment group (satelizumab or placebo) in a 1:1 ratio. Randomization will be stratified according to the following criteria:
[0730] * Patient population: Newly diagnosed patients and patients with incomplete response (as described in section 4.1.1)
[0731] *area
[0732] Estimated sample sizes required to demonstrate efficacy of mRS were calculated separately for the NMDARAIE and LGI1 AIE cohorts.
[0733] Based on these assumptions and using a two-sided significance level of 5%, the sample sizes to achieve 80% power for each cohort were estimated to be 102 participants (51 in each group) in the NMDARAIE cohort and 50 participants (25 in each group) in the LGI1 AIE cohort.
[0734] 7.3 Statistical analysis
[0735] The Statistical Analysis Plan (SAP) will be completed before the study is unblinded and the database is locked and will include a more technical and detailed description of the statistical analyses described in this section. This section is a summary of the planned statistical analyses of the most important endpoints (including the primary endpoint and key secondary endpoints).
[0736] 7.3.1 Primary End Point
[0737] 7.3.1.1 Primary efficacy measures and estimates
[0738] The primary efficacy objective is to evaluate the effect of satelizumab versus placebo on disability and clinical severity in patients with NMDAR and LGI1 encephalitis. The primary comparison of interest is the difference between the placebo and satelizumab groups in the proportion of participants who achieve at least a 1-point improvement from baseline in the mRS at Week 24 without the use of rescue therapy. The primary efficacy measure will be assessed separately in the NMDAR and LGI1 AIE cohorts.
[0739] If a participant withdraws from treatment, the reason for withdrawal will be categorized as study drug or condition related (SDCR) or non-study drug or condition related (NSDCR). More details on this categorization will be provided in the SAP. The primary comparison will include participants who withdrew for SDCR and NSDCR reasons, assuming that participants who withdrew for NSDCR reasons will continue to receive randomized treatment.
[0740] The main comparisons were made regardless of whether participants interrupted treatment (e.g. due to infection) or changes in background treatment were not considered rescue.
[0741] The elements of the primary estimand are defined in Table 4 and assess the proportion of participants who had an improvement of 1 or more points from baseline in the mRS at week 24 without the use of rescue therapy, regardless of whether withdrawal from study treatment due to SDCR, treatment interruption, or change in background therapy was not considered rescue, assuming that participants who withdrew due to NSDCR would continue to receive randomized treatment. The primary analysis methods and sample size were determined consistent with the primary estimand.
[0742] [Table 4]
[0743] Mainly measured attributes
[0744]
[0745] LGI1 = leucine-rich glioma inactivated 1; mRS = modified Rankin scale; NMDAR = N-methyl-D-aspartate receptor; NSDCR = not related to study drug or condition; SDCR = related to study drug or condition.
[0746] aTreatment policy: The value of this variable is used regardless of whether a concurrent event occurs.
[0747] b Assumption: Imagine a scenario in which no concurrent events occur.
[0748] c Composite: Incorporates concurrent events into the definition of the endpoint.
[0749] The SAP will detail additional estimates for different approaches to dealing with intercurrent events and include a treatment policy approach for intercurrent events with rescue therapy.
[0750] 7.3.1.2 Missing Data Handling
[0751] If data are missing, longitudinal mRS data will be imputed and the responder definition (improvement of at least 1 point in mRS) will then be applied. For NSDCR withdrawals, data will be censored at the time of withdrawal from treatment. Any data collected after NSDCR withdrawal will be ignored. Missing data after withdrawals identified as NSDCR (including use of rescue therapy) will be imputed using a multiple imputation method based on the “missing at random” assumption. Missing data after withdrawals identified as SDCR will be imputed using a reference-based multiple imputation method with a “replicate reference” assumption. Use of rescue therapy will be inferred based on the placebo group. This approach will only be used if observed data are not available after treatment withdrawal. If observed data are available, they will continue to be included in the analysis. Data after treatment interruptions (e.g. due to infection) and changes in background therapy that are not considered rescue will be included in the analysis. The robustness of the main estimation methods will be explored with a range of sensitivity estimators based on different assumptions underlying the multiple imputation strategy and the classification of treatment withdrawal events concurrent with withdrawal as SDCR or NSDCR.
[0752] Additional details will be provided in SAP.
[0753] 7.3.2 Secondary End Points
[0754] The first endpoint to be tested in both cohorts will be the primary endpoint. Subsequently, analyses of secondary endpoints will follow the hierarchy of the specific cohort. The order of secondary endpoints shown below does not necessarily reflect the hierarchy of each cohort.
[0755] The following secondary efficacy endpoints will be analyzed using the time and amount of events estimated:
[0756] *Time to improvement of at least 1 point from baseline in mRS score without rescue therapy
[0757] * Timing of rescue therapy
[0758] * Time to seizure freedom (seizure freedom defined as at least 6 consecutive weeks without seizures) or time to cessation of status epilepticus without rescue therapy
[0759] The following secondary efficacy endpoints will be analyzed using mean change estimators and measures:
[0760] *Change from baseline in CASE score at week 24
[0761] The following secondary efficacy endpoints will be analyzed using mean score estimators and estimates:
[0762] *Total MOCA score for Week 24
[0763] *RAVLT score at week 24 (LGI1 AIE cohort)
[0764] The following secondary efficacy endpoints will be analyzed using categorical score estimators and measures:
[0765] *mRS score at week 24 (measured on a 7-point scale; NMDAR AIE cohort)
[0766] Supplementary estimates for each endpoint will be detailed in the SAP.
[0767] 7.3.2.1 Events to be measured and time of estimation
[0768] The elements of the time to event being measured are defined using the time to rescue therapy endpoint as an example in Table 5. The comparison of interest was the difference in time to rescue therapy between the placebo and satelizumab groups, regardless of whether SDCR withdrawal from study treatment, treatment interruption, or background therapy change was not considered rescue, and it was assumed that participants with NSDCR withdrawals would continue to receive their randomized treatment.
[0769] [Table 5]
[0770] The property of the time at which the event is measured
[0771]
[0772] LGI1 = leucine-rich glioma inactivated 1; NMDAR = N-methyl-D-aspartate receptor; NSDCR = not related to study drug or condition; SDCR = related to study drug or condition.
[0773] a Treatment policy: The value of this variable is used regardless of whether a concurrent event occurs.
[0774] b Assumption: Imagine a scenario in which no concurrent events occur.
[0775] cComposite: Incorporates concurrent events into the definition of the endpoint.
[0776] 7.3.2.2 Mean change estimand and estimator
[0777] The elements of the mean changes measured are defined in Table 6. The comparison of interest was the difference in change from baseline in CASE score at week 24 between the placebo and satelizumab groups, regardless of whether SDCR withdrawal from study treatment, treatment interruption, or background therapy change was not considered rescue, assuming that rescue therapy had not been available, and assuming that participants with NSDCR withdrawals would continue to receive their randomized treatment.
[0778] [Table 6]
[0779] The average change in the property being measured
[0780]
[0781] CASE=Clinical Assessment Scale for Encephalitis; LGI1=leucine-rich glioma inactivated 1; MMRM=mixed model repeated measures; NMDAR=N-methyl-D-aspartate receptor; NSDCR=not related to study drug or condition; SDCR=related to study drug or condition.
[0782] a Treatment policy: The value of this variable is used regardless of whether a concurrent event occurs.
[0783] b Assumption: Imagine a scenario in which no concurrent events occur.
[0784] 7.3.2.3 Mean score estimator and estimator
[0785] Taking the MOCA total score endpoint as an example, the elements of the mean score being measured are defined in Table 7. The comparison of interest was the difference between the MOCA total scores in the placebo and satelizumab groups at Week 24, regardless of whether SDCR withdrawals from study treatment, treatment interruptions, or changes in background therapy were not considered rescue, assuming that rescue therapy was not yet available, and assuming that participants with NSDCR withdrawals would continue to receive their randomized treatment.
[0786] [Table 7]
[0787] The average score of the attribute being measured
[0788]
[0789] LGI1 = leucine-rich glioma inactivated 1; MOCA = Montreal Cognitive Assessment; MMRM = mixed-model repeated measures; NMDAR = N-methyl-D-aspartate receptor; NSDCR = not related to study drug or condition; SDCR = related to study drug or condition.
[0790] a Treatment policy: The value of this variable is used regardless of whether a concurrent event occurs.
[0791] b Assumption: Imagine a scenario in which no concurrent events occur.
[0792] 7.3.2.4 Categorical scoring estimands and estimators
[0793] The elements of the categorical scores being measured are defined in Table 8. The comparison of interest was the difference between the placebo and satelizumab groups in the mRS score at Week 24, regardless of whether SDCR withdrawal from study treatment, treatment interruption, or background therapy change was not considered rescue, assuming that rescue therapy had not been available, and assuming that participants with NSDCR withdrawals would continue to receive their randomized treatment.
[0794] [Table 8]
[0795] Categorical rating of the attribute being measured
[0796]
[0797] LGI1 = leucine-rich glioma inactivated 1; mRS = modified Rankin scale; NMDAR = N-methyl-D-aspartate receptor; NSDCR = not related to study drug or condition; SDCR = related to study drug or condition.
[0798] a Treatment policy: The value of this variable is used regardless of whether a concurrent event occurs.
[0799] b Assumption: Imagine a scenario in which no concurrent events occur.
[0800] 7.3.2.5 Safety Analysis
[0801] Safety will be assessed through summaries of study treatment exposure, adverse events, changes in laboratory test results, and changes in vital signs, weight, height (<18 years only), and electrocardiogram.
[0802] Study treatment exposure (eg, duration of treatment, total dose received, and dose modifications) will be summarized with descriptive statistics.
[0803] All verbatim adverse event terms will be mapped to Medical Dictionary for Regulatory Activities thesaurus terms, and adverse event severity will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. All adverse events, serious adverse events, adverse events leading to death, adverse events of special interest, and adverse events that occurred at or after the first dose of study treatment and led to discontinuation of study treatment (i.e., treatment-emergent adverse events) will be summarized using the mapped term, appropriate thesaurus level, and severity. For events of varying severity, the highest grade will be used in the summary. Deaths and causes of death will be summarized.
[0804] Relevant laboratory, vital sign (pulse rate, respiratory rate, blood pressure, pulse oximetry, and temperature), and ECG data will be displayed over time and, where appropriate, graded. In addition, baseline and post-baseline maximum severity grades will be summarized using a shift sheet for selected laboratory tests. Changes in vital signs, weight, height (<18 years only), and ECG will be summarized.
[0805] 7.3.3 Exploratory End Points
[0806] Subgroup analyses will be performed for the following groups:
[0807] *Adolescent participants with NMDAR encephalitis
[0808] *Participants with possible NMDAR encephalitis
[0809] Additional details regarding the definitions and analyses of exploratory endpoints will be provided in the SAP.
[0810] 7.3.4 Other analyses
[0811] 7.3.4.1 Pharmacokinetic Analysis
[0812] The PK analysis population consists of all participants in the safety analysis set who have at least one valid post-dose concentration result (with dose record and sampling time).The trial will evaluate the PK characteristics of satelizumab treatment by summary statistics and nonlinear mixed effects analysis (popPK).
[0813] Satlizumab concentration data and popPK analysis results will be reported separately from the CSR.
[0814] 7.3.4.2 Immunogenicity Analysis
[0815] The immunogenicity analysis population will consist of all participants who have at least one ADA assessment. Participants will be grouped according to treatment received or, if not receiving treatment prior to discontinuation of the study, according to assigned treatment.
[0816] The number and proportion of ADA-positive participants and ADA-negative participants will be summarized by treatment group at baseline (baseline prevalence) and after drug administration (post-baseline incidence). When determining the post-baseline incidence, if the participant shows a treatment-induced ADA response or a treatment-enhanced ADA response, the participant is considered ADA-positive. ADA is negative or has missing data at baseline, but participants who have ADA reactions after exposure to the study drug have treatment-induced ADA reactions. Participants who are positive for ADA at baseline and have a titer of at least 4 times (0.60 titer units) higher than the titer of the baseline sample in one or more post-baseline samples have a treatment-enhanced ADA response. If the participant is ADA-negative or has missing data at baseline, and all post-baseline samples are negative, or if they are ADA-positive at baseline, but the titer of no post-baseline sample is at least 4 times (0.60 titer units) higher than the titer of the baseline sample (treatment is not affected), the participant is considered ADA-negative.
[0817] The percentage of participants with positive or negative ADA results for satelizumab is presented in the table. PK, PD, efficacy parameters, and safety will be summarized by anti-satelizumab antibody (i.e., satelizumab ADA) status.
[0818] 7.3.4.3 Pharmacodynamic analysis
[0819] Serum IL-6 and sIL-6R levels will be summarized graphically and descriptively according to treatment group and time point.
[0820] 7.4 Interim Analysis
[0821] 7.4.1 Planned interim pharmacokinetic analysis
[0822] An interim PK analysis will be performed at week 8 of treatment to confirm that the achieved exposure (and predicted RO) is within the expected target range. If the achieved exposure (and predicted RO) is not within the expected target range, the dose may be adjusted to 120 mg, 180 mg, and 240 mg for participants weighing <40 kg, 40 to 100 kg (inclusive), and >100 kg, respectively. The selected dosing regimen will be associated with an exposure that does not significantly exceed the existing exposure safety range.
[0823] The iDMC will make a recommendation on whether (i) the trial can continue at the initial dose or (ii) the dose can be adjusted to a pre-specified higher dose.
[0824] 7.4.2 Optional interim analysis
[0825] To accommodate information that may emerge during the course of this study, the sponsor may elect to conduct an interim futility analysis. The following are guidelines to ensure that the study continues to meet the highest standards of integrity when the optional interim analysis is performed.
[0826] If an interim analysis is performed, the sponsor will remain blinded. The interim analysis will be performed by an external statistical panel and reviewed by the iDMC. The interaction between the iDMC and the sponsor will be as specified in the iDMC Charter.
[0827] The decision to conduct an optional interim analysis, along with the rationale, timeline, and statistical details of the analysis, will be documented in SAP. The iDMC charter will be updated to document the iDMC’s potential recommendation to the sponsor based on the results of the analysis (continue the study without modification, stop the study if it is not effective), and the iDMC charter will also be provided to the relevant health authorities.
[0828] If the interim analysis results indicate that the study may be stopped for futility, the threshold for declaring futility may include an assessment of the predicted probability of achieving statistical significance for a specified endpoint. The criteria for recommending stopping the study for futility may be added to the iDMC charter and will be documented in the SAP.
[0829] Industrial Applicability
[0830] The present invention provides a method for treating autoimmune encephalitis, such as NMDAR or LGI1 encephalitis, and reducing the risk of recurrence of the encephalitis, comprising an anti-IL-6 receptor antibody or an antigen-binding fragment thereof. The present invention also provides a drug or pharmaceutical composition for treating or reducing the risk of recurrence of the encephalitis, comprising an anti-IL-6 receptor antibody or an antigen-binding fragment thereof. The present invention also provides a method for treating or reducing the risk of recurrence of the encephalitis by administering an anti-IL-6 receptor antibody or an antigen-binding fragment thereof to a subject in need of the anti-IL-6 receptor antibody or an antigen-binding fragment thereof.
[0831] References
[0832] Abboud H, Probasco J, Irani SR, et al. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J Neurol NeurosurgPsychiatry 2021. doi:10.1136 / jnnp-2020-325302.
[0833] Archarya JN,Hani A,Thirumala P et al.Guideline 3:Aproposal forstandard montages to be used in clinical EEG.Am Clin Neurophysiol Soc2016:1-16.
[0834] Armangue T,Spatola M,Vlagea A,et al.Frequency,symptoms,risk factors,and outcomes of autoimmune encephalitis after herpes simplex encephalitis:aprospective observational study and retrospective analysis.Lancet Neurol2018;17:760-72.
[0835] Banks JL,Marotta CA.Outcomes validity and reliability of the modifiedRankin scale:implications for stroke clinical trials:a literature review andsynthesis.Stroke 2007;38:1091-6.
[0836] Beck AT,Ward CH,Mendelson M,et al.An inventory for measuringdepression.Arch Gen Psychiatry 1961;4:561-71.
[0837] Bien CG,Vincent A,Barnett MH,et al.Immunopathology of autoantibody-associated encephalitides:clues for pathogenesis.Brain 2012 May;135(Pt5):1622-38.
[0838] Brooks R.EuroQol:the current state of play.Health Policy 1996;37:53-72.
[0839] Cadena R,Shoykhet M,Ratcliff J.Emergency neurological life support:intracranial hypertension and herniation.Neurocrit Care 2017;27(Suppl 1):82-8.
[0840] Dalmau J,Armangue T,Planaguma J,et al.An update on anti-NMDAreceptorencephalitis for neurologists and psychiatrists:mechanisms and models.LancetNeurology 2019;11:1045-1057.
[0841] Ding Y-W,Pan S-Y,Xie W,et al.Elevated soluble fas and fasLincerebrospinal fluid and serum of patients with anti-N-methyl-D-aspartatereceptor encephalitis.Front Neurol 2018 9:904.
[0842] Dubey D,Pittock S,Kelly C,et al.Autoimmune encephalitisepidemiologyand a comparison to infectious encephalitis.Ann Neurol 2018;83:166-77.
[0843] Dubey D,Sawhney A,Greenberg B,et al.The spectrum ofautoimmuneencephalopathies.J Neuroimmunol 2015;15:93-7.
[0844] EuroQol Group.EuroQol:a new facility for the measurement of health-related quality of life.Health Policy 1990;16:199-208.
[0845] Food and Drug Administration.Guidance for industry,"Enrichmentstrategies for clinical trials to support approval of human drugsand biologicalproducts"[March 2019].Available from:https: / / www.fda.gov / regulatory-information / search-fda-guidance-documents / enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products.
[0846] Fisk JD,Pontefract A,Ritvo PG,et al.The impact of fatigue onpatientswith multiple sclerosis.Can J Neurol Sci 1994a;21:9-14.
[0847] Fisk JD,Ritvo PG,Ross L,et al.Measuring the functional impact offatigue:initial validation of the Fatigue Impact Scale.Clin Infect Dis1994b;18(Supplement_1):S79-83.
[0848] Gadoth A,Pittock S,Dubey D,et al.Expanded phenotypes andoutcomesamong 256 LGI1 / CASPR2-IgG-positive patients.Ann Neurol.2017;82:79-92.
[0849] Gadoth A,Zekeridou A,Klein CJ,et al.Elevated LGI1-IgG CSFindexpredicts worse neurological outcome.Ann Clin Transl Neurol 2018;5:646-50.
[0850] Graus G,Titulaer M,Benseler S,et al.Aclinical approach to diagnosisofautoimmune encephalitis.Lancet Neurol 2016;15:391-404.
[0851] Gruter T,Ott A,Meyer W,et al.Effects of IVIg treatment onautoantibodytesting in neurological patients:marked reduction in sensitivityby reliablespecificity.J Neurology 2020;267(1).
[0852] Hang HL,Zhang JH,Chen DW,et alP.Clinical characteristics ofcognitiveimpairment and 1-year outcome in patients with anti-LGI1 antibodyencephalitis.Front Neurol 2020;11:852.
[0853] Harrison JK,McArthur KS,Quinn TJ.Assessment scales in stroke:clinimetric and clinical considerations.Clin Interv Aging 2013;8:201-11.
[0854] Helmstaedter C,Hansen N,Leelaarporn P,et al.Specific B-and T-cellpopulations are associated with cognition in patients with epilepsy andantibodypositive and negative suspected limbic encephalitis.J Neurol 2021;268:455-66.
[0855] Herdman M,Gudex C,Lloyd A,et al.Development and preliminary testingofthe new five-level version of EQ-5D(EQ-5D-5L).Qual Life Res2011;20:1727-36.
[0856] Ho ACC,Mohammad SS,Pillai SC,et al.High sensitivity and specificityinproposed clinical diagnostic criteria for anti-N-methyl-D-aspartatereceptorencephalitis.Dev Med Child Neurol 2017;59:1256-60.
[0857] Hughes EG,Peng X,Gleichman AJ,et al.Cellular and synapticmechanismsof anti-NMDA receptor encephalitis.J Neurosci 2010;30:5866-75.
[0858] Janssen MF,Pickard AS,Golicki D,et al.Measurement properties oftheEQ-5D-5L compared to the EQ-5D-3L across eight patient groups:a multi-country study.Qual Life Res 2013;22:1717-27.
[0859] Johns MW.Anew method for measuring daytime sleepiness:theEpworthScale.Sleep 1991;14:540-5.
[0860] Jun J-S,Lee S-T,Kim R,et al.Tocilizumab treatment for earlytreatmentrefractory status epilepticus.Ann Neurol 2018;84:940-5.
[0861] Kaneko A,Kaneko J,Tominaga N et al.Pitfalls in clinical diagnosis ofanti-NMDA receptor encephalitis.J Neurol 2018 Mar;265:586-96.
[0862] Kirmani B,Barr D,Robinson DM,et al.Management of autoimmunestatusepilepticus.Front Neurol 2018;9:259.
[0863] Kluger BM,Krupp LB,Enoka RM.Fatigue and fatigability inneurologicillnesses:proposal for a unified taxonomy.Neurology 2013;80:409-16.
[0864] Krogias C,Hoepner R,Muller A,et al.Successful treatment of anti-Caspr2syndrome by interleukin 6 receptor blockade throughtocilizumab.JAMANeurol 2013;70:1056-9.
[0865] Lee WJ,Lee ST,Byun JI,et al.Rituximab treatment for autoimmune limbicencephalitis in an institutional cohort.Neurology 2016a:86:1683-91.
[0866] Lee WJ,Lee ST,Moon J,et al.Tocilizumab in autoimmune encephalitis refractory to rituximab:an institutional cohort study.Neurotherapeutics2016b:13:824-32.
[0867] Lee WJ, Lee ST, Shin YW, et al.Teratoma removal, steroids, IVIG, rituximaband tocilizumab(T-SIRT) in anti-NMDAR encephalitis.
[0868] Leypoldt F,Hoftberger R,Titulaer MJ,et al.Investigations on CXCL13inanti-N-methyl-D-aspartate receptor encephalitis:a potential biomarkeroftreatment response.JAMANeurol.2015:72:180-6.
[0869] Leypoldt F,Wandinger KP,Bien C,et al.Autoimmune encephalitis.EurNeurol Rev 2013:8:31-7.
[0870] Lim JA,Lee ST,Moon J.Development of the clinical assessment scale for autoimmune encephalitis.Ann Neurol 2019:85:352-8.
[0871] Martinez-Hernandez E,Horvath J,Shiloh-Malawsky Y,et al.Analysisofcomplement and plasma cells in the brain of patients with anti-NMDARencephalitis.Neurology 2011;7:589-93.
[0872] Mikasova L,De Rossi P,Bouchet D,et al.Disrupted surface cross-talkbetween NMDAand Ephrin-B2 receptors in anti-NMDA encephalitis.Brain2012;135:1606-21.
[0873] Moscato EH,Peng X,Jain A,et al.Acute mechanisms underlyingantibodyeffects in anti-N-methyl-D-aspartate receptor encephalitis.AnnNeurol2014;76:108-19.
[0874] Nishida H,Kohyama K,Kumada S,et al.Evaluation of thediagnosticcriteria for anti-NMDA receptor encephalitis in Japanesechildren.Neurology2021;96:e2070-e2077.
[0875] Ohkawa T,Fukata Y,Miwako Y,et al.Autoantibodies to epilepsy-relatedLGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction andreducesynaptic AMPA receptors.J Neurosci 2013;33:18161-74.
[0876] Peaker A,Stewart LE.Rey's Auditory-Verbal Learning Test-areview.DevClin Exper Neuropsychology 1989:219-36.
[0877] Petit-Pedrol M,Sell J,Planaguma J,et al.LGI1 antibodies alter Kv1.1andAMPA receptors changing synaptic excitability,plasticity andmemory.Brain2018;141:3144-59.
[0878] Randell R,Adams A,Van Mater H.Tocilizumab in refractoryautoimmuneencephalitis:a series of pediatric cases.Ped Neurology 2018;86:66-8.
[0879] Rankin J.Cerebral vascular accidents in patients over the age of 60:II.Prognosis.Scott Med J 1957;2:200-15.
[0880] Rosch RE,Wright S,Cooray G,et al.NMDA-receptor antibodiesaltercortical microcircuit dynamics.Proc Natl Acad Sci USA 2018;115:E9916-25.
[0881] Shin Y-W,Lee S-T,Park K-I,et al.Treatment strategies forautoimmuneencephalitis.Ther Adv Neurol Disord 2018;11:1756285617722347.
[0882] Spreen O,Strauss E.A compendium of neuropsychological tests:administration,norms,and commentary.New York:Oxford University Press,1991.
[0883] Titulaer M,McCracken L,Gabilondo I,et al.Treatment andprognosticfactors for long-term outcome in patients with anti-NMDA receptorencephalitis:an observational cohort study.Lancet Neurol 2013;12:157-65.
[0884] van Sonderen A,Thijs R,Coenders E,et al.Anti-LGI1 encephalitis:clinicalsyndrome and long-term follow-up.Neurology 2016;87:1449-56.
[0885] Venkatesan A,Tunkel AR,Bloch KC,et al.Case definitions,diagnosticalgorithms,and priorities in encephalitis:consensus statement oftheInternational Encephalitis Consortium.Clin Infect Dis 2013;57:1114-28.
[0886] Wang X,Ma C,Liu CY et al.Neuronal NMDAR currents of thehippocampusand learning performance in autoimmune anti-NMDARencephalitis and involvementof TNF-alpha and IL-6.Front Neurol 2019;10:684.
[0887] Wilson JL,Hareendran A,Hendry A,et al.Reliability of themodifiedRankin Scale across multiple raters:benefits of a structuredinterview.Stroke2005;36:777-81.
Claims
1. A medicament for treating autoimmune encephalitis (AIE) in a subject, comprising satelizumab.
2. The medicament of claim 1, which is used to delay the recurrence of autoimmune encephalitis, reduce the frequency of its recurrence, reduce the severity of its recurrence, or reduce the risk of its recurrence.
3. The medicament of claim 1 or 2, wherein the autoimmune encephalitis is anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis or anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis.
4. The drug of any one of claims 1 to 3, wherein the drug is administered subcutaneously to a subject.
5. The medicament of any one of claims 1-4, wherein the medicament provides 60 mg, 120 mg, 180 mg or 240 mg dosage units of satelizumab to a subject.
6. The drug according to any one of claims 1 to 5, wherein the drug is used in a manner of administering 60 mg of satelizumab per administration to a subject weighing less than 40 kg.
7. The drug according to any one of claims 1 to 5, wherein the drug is used in a manner of administering 120 mg of satelizumab per administration to a subject weighing less than 40 kg.
8. The drug according to any one of claims 1 to 5, wherein the drug is used in a manner of administering 120 mg of satelizumab per administration to a subject weighing 40 to 100 kg.
9. The drug according to any one of claims 1 to 5, wherein the drug is used in a manner of administering 180 mg of satelizumab per administration to a subject weighing 40 to 100 kg.
10. The drug according to any one of claims 1 to 5, wherein the drug is used in a manner of administering 180 mg of satelizumab per administration to a subject weighing more than 100 kg.
11. The drug according to any one of claims 1 to 5, wherein the drug is used in a manner of administering 240 mg of satelizumab per administration to a subject weighing more than 100 kg.
12. The drug of any one of claims 1-11, wherein the drug is administered to the subject once every two weeks (Q2W) for three times, and thereafter once every four weeks (Q4W).
13. The drug according to any one of claims 1 to 12, wherein The drug is used in combination with immunosuppressive therapy (IST).
14. The medicament of claim 13, wherein the IST is a therapy using: (i) an immunosuppressant selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF), and intravenous (IV) cyclophosphamide; (ii) oral corticosteroids (OCS); or (iii) a combination of (i) and (ii).
15. The medicament of claim 14, wherein the immunosuppressant comprises prednisone, prednisolone or an equivalent thereof.
16. The medicament of claim 5, which is administered via a subcutaneous administration device.
17. The medicament of claim 16, wherein the subcutaneous administration device is a prefilled syringe (PFS) optionally comprising a needle safety device (PFS-NSD), or an autoinjector (AI).
